Maarten Boers

Q: What Schools Are Affiliated With Maarten Boers

Maarten Boers is affiliated with the following schools: University of Amsterdam, Vrije Universiteit Amsterdam, University of Twente, Eindhoven University of Technology, Delft University of Technology

Maarten Boers's AcademicInfluence.com Rankings

Maarten Boers

Computer Science

#3838

World Rank

#4033

Historical Rank

Machine Learning

#570

World Rank

#577

Historical Rank

Artificial Intelligence

#770

World Rank

#782

Historical Rank

Database

#1094

World Rank

#1151

Historical Rank

computer-science Degrees

Download Badge

Computer Science

Maarten Boers's Degrees

PhD Computer Science Delft University of Technology
Masters Artificial Intelligence University of Amsterdam
Bachelors Computer Science University of Amsterdam

Similar Degrees You Can Earn

Why Is Maarten Boers Influential?

(Suggest an Edit or Addition)

(See a Problem?)

Maarten Boers's Published Works

Number of citations in a given year to any of this author's works

Total number of citations to an author for the works they published in a given year. This highlights publication of the most important work(s) by the author

Published Works

Development of AMSTAR: a measurement tool to assess the methodological quality of systematic reviews (2007) (3653)
American College of Rheumatology. Preliminary definition of improvement in rheumatoid arthritis. (1995) (2640)
EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2016 update (2010) (2474)
The Delphi list: a criteria list for quality assessment of randomized clinical trials for conducting systematic reviews developed by Delphi consensus. (1998) (2183)
EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2013 update (2013) (1711)
The American College of Rheumatology preliminary core set of disease activity measures for rheumatoid arthritis clinical trials. The Committee on Outcome Measures in Rheumatoid Arthritis Clinical Trials. (1993) (1650)
AMSTAR is a reliable and valid measurement tool to assess the methodological quality of systematic reviews. (2009) (1554)
EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2019 update (2020) (1453)
American College of Rheumatology/European League Against Rheumatism Provisional Definition of Remission in Rheumatoid Arthritis for Clinical Trials (2011) (1163)
Randomised comparison of combined step-down prednisolone, methotrexate and sulphasalazine with sulphasalazine alone in early rheumatoid arthritis (1997) (1138)
Effectiveness of positron emission tomography in the preoperative assessment of patients with suspected non-small-cell lung cancer: the PLUS multicentre randomised trial (2002) (814)
Recommendations for a core set of outcome measures for future phase III clinical trials in knee, hip, and hand osteoarthritis. Consensus development at OMERACT III. (1997) (730)
The OMERACT filter for Outcome Measures in Rheumatology. (1998) (669)
COBRA combination therapy in patients with early rheumatoid arthritis: long-term structural benefits of a brief intervention. (2002) (660)
Developing core outcome measurement sets for clinical trials: OMERACT filter 2.0. (2014) (637)
How to select outcome measurement instruments for outcomes included in a “Core Outcome Set” – a practical guideline (2016) (546)
External Validation of a Measurement Tool to Assess Systematic Reviews (AMSTAR) (2007) (520)
OMERACT: An international initiative to improve outcome measurement in rheumatology (2007) (497)
Safety of low dose glucocorticoid treatment in rheumatoid arthritis: published evidence and prospective trial data (2005) (484)
Progression of radiologic damage in patients with rheumatoid arthritis in clinical remission. (2004) (423)
Standardised nomenclature for glucocorticoid dosages and glucocorticoid treatment regimens: current questions and tentative answers in rheumatology (2002) (408)
Effects of glucocorticoids on radiological progression in rheumatoid arthritis. (2007) (363)
Does rheumatoid arthritis equal diabetes mellitus as an independent risk factor for cardiovascular disease? A prospective study. (2009) (361)
Rheumatoid arthritis versus diabetes as a risk factor for cardiovascular disease: a cross-sectional study, the CARRÉ Investigation (2008) (356)
American College of Rheumatology/European League Against Rheumatism provisional definition of remission in rheumatoid arthritis for clinical trials. (2011) (354)
Minimal clinically important differences: review of methods. (2001) (340)
Reporting disease activity in clinical trials of patients with rheumatoid arthritis: EULAR/ACR collaborative recommendations. (2008) (318)
EULAR evidence-based recommendations on the management of systemic glucocorticoid therapy in rheumatic diseases (2007) (309)
World Health Organization and International League of Associations for Rheumatology core endpoints for symptom modifying antirheumatic drugs in rheumatoid arthritis clinical trials. (1994) (309)
Incidence of retinoblastoma in children born after in-vitro fertilisation (2003) (306)
Influence of glucocorticoids and disease activity on total and high density lipoprotein cholesterol in patients with rheumatoid arthritis (2003) (289)
Minimally important change determined by a visual method integrating an anchor-based and a distribution-based approach (2006) (289)
Criteria for clinically important changes in outcomes: development, scoring and evaluation of rheumatoid arthritis patient and trial profiles. OMERACT Committee. (1993) (280)
Differences in descriptions of Kellgren and Lawrence grades of knee osteoarthritis (2008) (278)
Arthritis development in patients with arthralgia is strongly associated with anti-citrullinated protein antibody status: a prospective cohort study (2009) (276)
Deciding on progression of joint damage in paired films of individual patients: smallest detectable difference or change (2004) (274)
Health economics in the field of osteoarthritis: an expert's consensus paper from the European Society for Clinical and Economic Aspects of Osteoporosis and Osteoarthritis (ESCEO). (2013) (269)
The relationship between disease activity and radiologic progression in patients with rheumatoid arthritis: a longitudinal analysis. (2004) (265)
The art of quality assessment of RCTs included in systematic reviews. (2001) (251)
Looking for important change/differences in studies of responsiveness. OMERACT MCID Working Group. Outcome Measures in Rheumatology. Minimal Clinically Important Difference. (2001) (247)
Core outcome domains for clinical trials in non-specific low back pain (2015) (241)
Defining conditions where long-term glucocorticoid treatment has an acceptably low level of harm to facilitate implementation of existing recommendations: viewpoints from an EULAR task force (2016) (235)
Reliability and sensitivity to change of a simplification of the Sharp/van der Heijde radiological assessment in rheumatoid arthritis. (1999) (233)
ACR and EULAR improvement criteria have comparable validity in rheumatoid arthritis trials. American College of Rheumatology European League of Associations for Rheumatology. (1999) (230)
Outcomes from the Patient Perspective Workshop at OMERACT 6. (2003) (224)
EULAR evidence-based and consensus-based recommendations on the management of medium to high-dose glucocorticoid therapy in rheumatic diseases (2013) (222)
Core outcome measurement instruments for clinical trials in nonspecific low back pain (2017) (221)
Minimal disease activity for rheumatoid arthritis: a preliminary definition. (2005) (203)
Measurement Properties of Visual Analogue Scale, Numeric Rating Scale, and Pain Severity Subscale of the Brief Pain Inventory in Patients With Low Back Pain: A Systematic Review. (2019) (201)
Association of baseline levels of markers of bone and cartilage degradation with long-term progression of joint damage in patients with early rheumatoid arthritis: the COBRA study. (2002) (200)
The ratio of circulating osteoprotegerin to RANKL in early rheumatoid arthritis predicts later joint destruction. (2006) (198)
OMERACT conference on outcome measures in rheumatoid arthritis clinical trials: introduction. (1993) (185)
Understanding the window of opportunity concept in early rheumatoid arthritis. (2003) (177)
Towards global consensus on outcome measures for atopic eczema research: results of the HOME II meeting (2012) (176)
Minimal clinically important improvement and patient acceptable symptom state for subjective outcome measures in rheumatic disorders. (2007) (173)
Monitoring adverse events of low-dose glucocorticoid therapy: EULAR recommendations for clinical trials and daily practice (2010) (168)
Repeatability of 18F-FDG Uptake Measurements in Tumors: A Metaanalysis (2012) (166)
Determination of the minimal clinically important difference in rheumatoid arthritis joint damage of the Sharp/van der Heijde and Larsen/Scott scoring methods by clinical experts and comparison with the smallest detectable difference. (2002) (161)
Low-dose prednisone chronotherapy for rheumatoid arthritis: a randomised clinical trial (CAPRA-2) (2012) (161)
Twenty-eight-joint counts invalidate the DAS28 remission definition owing to the omission of the lower extremity joints: a comparison with the original DAS remission (2005) (160)
The interferon type I signature towards prediction of non-response to rituximab in rheumatoid arthritis patients (2012) (159)
EULAR points to consider in the development of classification and diagnostic criteria in systemic vasculitis (2010) (159)
Traditional versus up-front [18F] fluorodeoxyglucose-positron emission tomography staging of non-small-cell lung cancer: a Dutch cooperative randomized study. (2006) (156)
Second primary tumors in hereditary retinoblastoma: a register-based study, 1945-1997: is there an age effect on radiation-related risk? (2001) (156)
Content validity of patient-reported outcome measures: perspectives from a PROMIS meeting (2012) (156)
How to report radiographic data in randomized clinical trials in rheumatoid arthritis: guidelines from a roundtable discussion. (2002) (153)
Methods to monitor response to chemotherapy in non-small cell lung cancer with 18F-FDG PET. (2002) (151)
Comparison of different definitions to classify remission and sustained remission: 1 year TEMPO results (2005) (148)
The OMERACT Handbook (2014) (148)
Outcome measures for clinical research in sepsis: A report of the 2nd Cambridge Colloquium of the International Sepsis Forum (2005) (147)
Comparison between self-report measures and clinical observations of functional disability in ankylosing spondylitis, rheumatoid arthritis and fibromyalgia. (1994) (146)
A proposed revision to the ACR20: the hybrid measure of American College of Rheumatology response. (2007) (144)
Is group physical therapy superior to individualized therapy in ankylosing spondylitis? A randomized controlled trial. (1993) (144)
Preliminary core set of domains and reporting requirements for longitudinal observational studies in rheumatology. (1999) (143)
Cost-effectiveness of FDG-PET in staging non-small cell lung cancer: the PLUS study (2003) (139)
Outcome measures in rheumatoid arthritis randomised trials over the last 50 years (2013) (139)
ACR and EULAR improvement criteria have comparable validity in rheumatoid arthritis trials : Part 3: Rheumatoid Arthritis: Response (1998) (139)
Definitions and validation criteria for biomarkers and surrogate endpoints: development and testing of a quantitative hierarchical levels of evidence schema. (2007) (133)
Developing consensus on preliminary core efficacy endpoints for rheumatoid arthritis clinical trials. OMERACT Committee. (1993) (132)
Balneotherapy for rheumatoid arthritis. (2004) (130)
Reading radiographs in chronological order, in pairs or as single films has important implications for the discriminative power of rheumatoid arthritis clinical trials. (1999) (128)
Effect of dexamethasone on autoantibody levels and arthritis development in patients with arthralgia: a randomised trial (2009) (124)
Smallest detectable difference in radiological progression. (1999) (122)
Patient and rheumatologist perspectives on glucocorticoids: an exercise to improve the implementation of the European League Against Rheumatism (EULAR) recommendations on the management of systemic glucocorticoid therapy in rheumatic diseases (2009) (120)
Survival, comorbidities and joint damage 11 years after the COBRA combination therapy trial in early rheumatoid arthritis (2009) (117)
CHECK (Cohort Hip and Cohort Knee): similarities and differences with the Osteoarthritis Initiative (2008) (117)
Making an impact on mortality in rheumatoid arthritis: targeting cardiovascular comorbidity. (2004) (117)
Baseline RANKL:OPG ratio and markers of bone and cartilage degradation predict annual radiological progression over 11 years in rheumatoid arthritis (2010) (116)
COSMIN Risk of Bias tool to assess the quality of studies on reliability or measurement error of outcome measurement instruments: a Delphi study (2020) (112)
Markers for type II collagen breakdown predict the effect of disease-modifying treatment on long-term radiographic progression in patients with rheumatoid arthritis. (2004) (109)
Antibody development after COVID-19 vaccination in patients with autoimmune diseases in the Netherlands: a substudy of data from two prospective cohort studies (2021) (108)
Renal findings in rheumatoid arthritis: clinical aspects of 132 necropsies. (1987) (107)
Developing a Standardized Definition for Disease “Flare” in Rheumatoid Arthritis (OMERACT 9 Special Interest Group) (2009) (106)
Just released from the ASAS factory! First steps towards a disease activity score for ankylosing spondylitis (2008) (104)
Indirect comparison of tocilizumab and other biologic agents in patients with rheumatoid arthritis and inadequate response to disease-modifying antirheumatic drugs. (2010) (103)
It's Good to Feel Better But It's Better To Feel Good and Even Better to Feel Good as Soon as Possible for as Long as Possible. Response Criteria and the Importance of Change at OMERACT 10 (2011) (101)
A non-inferiority trial of an attenuated combination strategy (‘COBRA-light’) compared to the original COBRA strategy: clinical results after 26 weeks (2013) (100)
Impact of different descriptions of the Kellgren and Lawrence classification criteria on the diagnosis of knee osteoarthritis (2011) (100)
The OMERACT Core Set of Outcome Measures for Use in Clinical Trials of ANCA-associated Vasculitis (2011) (99)
Glucocorticoids in the treatment of early and late RA (2003) (99)
Reliability of measures of disease activity and disease damage in rheumatoid arthritis: implications for smallest detectable difference, minimal clinically important difference, and analysis of treatment effects in randomized controlled trials. (2001) (98)
Evidence-Based Rheumatology (2003) (98)
Three trajectories of activity limitations in early symptomatic knee osteoarthritis: a 5-year follow-up study (2013) (96)
Limited bone loss due to corticosteroids; a systematic review of prospective studies in rheumatoid arthritis and other diseases. (1997) (95)
Validity of the MACTAR questionnaire as a functional index in a rheumatoid arthritis clinical trial. The McMaster Toronto Arthritis. (2000) (95)
Early and aggressive treatment of rheumatoid arthritis patients affects the association of HLA class II antigens with progression of joint damage. (2002) (92)
Combination therapy in rheumatoid arthritis: updated systematic review. (1998) (92)
Detecting radiological changes in rheumatoid arthritis that are considered important by clinical experts: influence of reading with or without known sequence. (2002) (91)
Tight control and intensified COBRA combination treatment in early rheumatoid arthritis: 90% remission in a pilot trial (2008) (90)
Repair of erosions in rheumatoid arthritis does occur. Results from 2 studies by the OMERACT Subcommittee on Healing of Erosions. (2003) (88)
Recommendations for the conduct of clinical trials for drugs to treat or prevent sarcopenia (2015) (88)
Diagnostic accuracy of 18F-fluorodeoxyglucose positron emission tomography in the follow-up of papillary or follicular thyroid cancer. (2001) (88)
Radiologic features in juvenile idiopathic arthritis: a first step in the development of a standardized assessment method. (2003) (86)
Long-term outcome of juvenile idiopathic arthritis following a placebo-controlled trial: sustained benefits of early sulfasalazine treatment (2007) (86)
Balneotherapy and quality assessment: interobserver reliability of the Maastricht criteria list and the need for blinded quality assessment. (1998) (83)
Responsiveness of the core set, response criteria, and utilities in early rheumatoid arthritis (2000) (82)
The World Health Organisation International Classification of Functioning, Disability and Health: a conceptual model and interface for the OMERACT process. (2007) (82)
Inflammation and damage in an individual joint predict further damage in that joint in patients with early rheumatoid arthritis. (2001) (82)
Development of Outcome Measures for Large-vessel Vasculitis for Use in Clinical Trials: Opportunities, Challenges, and Research Agenda (2011) (82)
Defining remission in rheumatoid arthritis: results of an initial American College of Rheumatology/European League Against Rheumatism consensus conference. (2009) (82)
Methodological issues in radiographic scoring methods in rheumatoid arthritis. (1999) (81)
How to Choose Core Outcome Measurement Sets for Clinical Trials: OMERACT 11 Approves Filter 2.0 (2014) (81)
Evidence for predictive validity of remission on long‐term outcome in rheumatoid arthritis: A systematic review (2010) (78)
Serum 14-3-3η is a Novel Marker that Complements Current Serological Measurements to Enhance Detection of Patients with Rheumatoid Arthritis (2014) (78)
Value of ultrasonography as a marker of early response to abatacept in patients with rheumatoid arthritis and an inadequate response to methotrexate: results from the APPRAISE study (2015) (76)
Radiological scoring methods in ankylosing spondylitis: reliability and sensitivity to change over one year. (1999) (74)
Cost-effectiveness and cost-utility of combination therapy in early rheumatoid arthritis: randomized comparison of combined step-down prednisolone, methotrexate and sulphasalazine with sulphasalazine alone. COBRA Trial Group. Combinatietherapie Bij Reumatoïde Artritis. (1998) (73)
OMERACT Filter 2.1: Elaboration of the Conceptual Framework for Outcome Measurement in Health Intervention Studies (2019) (73)
Report from the fifth international consensus meeting to harmonize core outcome measures for atopic eczema/dermatitis clinical trials (HOME initiative) (2016) (72)
A modified Delphi exercise to determine the extent of consensus with OMERACT outcome domains for studies of acute and chronic gout (2007) (72)
Balneotherapy (or spa therapy) for rheumatoid arthritis. (2015) (71)
Minimal clinically important difference module: summary, recommendations, and research agenda. (2001) (71)
The patient perspective on remission in rheumatoid arthritis: 'You've got limits, but you're back to being you again'. (2015) (70)
A systematic review highlights the need to investigate the content validity of patient-reported outcome measures for physical functioning in patients with low back pain. (2018) (70)
Standard 5: Selection, Measurement, and Reporting of Outcomes in Clinical Trials in Children (2012) (69)
Balneotherapy for osteoarthritis. (2007) (69)
Eradication of Helicobacter pylori Does Not Reduce the Incidence of Gastroduodenal Ulcers in Patients on Long‐term NSAID Treatment: Double‐Blind, Randomized, Placebo‐Controlled Trial (2007) (68)
OMERACT 6 Economics Working Group report: a proposal for a reference case for economic evaluation in rheumatoid arthritis. (2003) (68)
Minimal disease activity, remission, and the long-term outcomes of rheumatoid arthritis. (2007) (66)
Reporting disease activity in clinical trials of patients with rheumatoid arthritis: EULAR/ACR collaborative recommendations (2008) (65)
The patient perspective on absence of disease activity in rheumatoid arthritis: a survey to identify key domains of patient-perceived remission (2015) (65)
Variability of precision in scoring radiographic abnormalities in rheumatoid arthritis by experienced readers. (2004) (64)
Assessing Quality of Sleep in Patients with Rheumatoid Arthritis (2009) (64)
Minimal clinically important difference in radiological progression of joint damage over 1 year in rheumatoid arthritis: preliminary results of a validation study with clinical experts. (2001) (63)
Consensus Dutch Health Assessment Questionnaire (2006) (63)
Exploring a new ultrasound score as a clinical predictive tool in patients with rheumatoid arthritis starting abatacept: results from the APPRAISE study (2016) (63)
Rheumatoid arthritis. Treatment of early disease. (2001) (62)
NSAIDS and selective COX-2 inhibitors: competition between gastroprotection and cardioprotection (2001) (62)
Intensive combination treatment regimens, including prednisolone, are effective in treating patients with early rheumatoid arthritis regardless of additional etanercept: 1-year results of the COBRA-light open-label, randomised, non-inferiority trial (2014) (61)
Subclinical renal dysfunction in rheumatoid arthritis. (1990) (60)
The OMERACT-OARSI Core Domain Set for Measurement in Clinical Trials of Hip and/or Knee Osteoarthritis (2019) (59)
Comparison of long-term clinical outcome with etanercept treatment and adalimumab treatment of rheumatoid arthritis with respect to immunogenicity. (2012) (59)
Perspective of patients with autoimmune diseases on COVID-19 vaccination (2021) (59)
Does updating improve the methodological and reporting quality of systematic reviews? (2006) (59)
Successful reduction of overexposure in patients with rheumatoid arthritis with high serum adalimumab concentrations: an open-label, non-inferiority, randomised clinical trial (2017) (58)
Balneotherapy for rheumatoid arthritis and osteoarthritis. (2000) (58)
Report from the OMERACT Hand Osteoarthritis Working Group: Set of Core Domains and Preliminary Set of Instruments for Use in Clinical Trials and Observational Studies (2015) (58)
Outcome Measures Used in Clinical Trials for Behçet Syndrome: A Systematic Review (2014) (57)
Economic evaluation of programs or interventions in the management of rheumatoid arthritis: defining a consensus-based reference case. (2003) (57)
The rate of NSAID-induced endoscopic ulcers increases linearly but not exponentially with age: a pooled analysis of 12 randomised trials (2006) (56)
Arthritis instantaneously causes collagen type I and type II degradation in patients with early rheumatoid arthritis: a longitudinal analysis (2005) (56)
Prevalence of cardiovascular diseases in psoriatic arthritis resembles that of rheumatoid arthritis (2010) (56)
Discordant perspectives of rheumatologists and patients on COBRA combination therapy in rheumatoid arthritis. (2008) (56)
Cardiovascular events in anti-neutrophil cytoplasmic antibody-associated vasculitis: a meta-analysis of observational studies (2018) (55)
Updating the OMERACT Filter: Implications for Patient-reported Outcomes (2014) (55)
Assessment of health‐related quality of life as an outcome measure in granulomatosis with polyangiitis (Wegener's) (2012) (55)
Comparison of cyclosporine and D-penicillamine for rheumatoid arthritis: a randomized, double blind, multicenter study. (1991) (54)
Recommendations for the registration of drugs used in the treatment of osteoarthritis: an update on biochemical markers. (2001) (54)
Confounding by Indication Probably Distorts the Relationship between Steroid Use and Cardiovascular Disease in Rheumatoid Arthritis: Results from a Prospective Cohort Study (2014) (54)
Cyclosporine in rheumatoid arthritis. (1992) (53)
Validity of area-under-the-curve analysis to summarize effect in rheumatoid arthritis clinical trials. (1999) (53)
Is there a preferred method for scoring activity of the spine by magnetic resonance imaging in ankylosing spondylitis? (2007) (52)
Development of a standardized method of assessment of radiographs and radiographic change in juvenile idiopathic arthritis: introduction of the Dijkstra composite score. (2005) (52)
Risk of serious adverse effects of biological and targeted drugs in patients with rheumatoid arthritis: a systematic review meta-analysis (2016) (52)
Neurologic outcome of surgical and conservative treatment of rheumatoid cervical spine subluxation: a systematic review. (2009) (51)
Reappraisal of OMERACT 8 Draft Validation Criteria for a Soluble Biomarker Reflecting Structural Damage Endpoints in Rheumatoid Arthritis, Psoriatic Arthritis, and Spondyloarthritis: The OMERACT 9 v2 Criteria (2009) (51)
Gastrointestinal events in at-risk patients starting non-steroidal anti-inflammatory drugs (NSAIDs) for rheumatic diseases: the EVIDENCE study of European routine practice (2013) (50)
Instrument Selection Using the OMERACT Filter 2.1: The OMERACT Methodology (2019) (50)
Taking baths: the efficacy of balneotherapy in patients with arthritis. A systematic review. (1997) (49)
Core Domain Set Selection According to OMERACT Filter 2.1: The OMERACT Methodology (2019) (48)
A prospective cohort study of 14-3-3η in ACPA and/or RF-positive patients with arthralgia (2016) (48)
A core outcome set for clinical trials on non-specific low back pain: study protocol for the development of a core domain set (2014) (48)
Cohort Profile: Cohort Hip and Cohort Knee (CHECK) study. (2016) (47)
Core outcome sets for research and clinical practice (2017) (47)
Long acting drug combinations in rheumatoid arthritis: a formal overview. (1991) (47)
Direct medical costs of traumatic thoracolumbar spine fractures (2005) (46)
Current status of outcome measures in vasculitis: focus on Wegener's granulomatosis and microscopic polyangiitis. Report from OMERACT 7. (2005) (46)
Practice, efficacy, and costs of thyroid nodule evaluation: a retrospective study in a Dutch university hospital. (2004) (46)
Why are Dutch rheumatologists reluctant to use the COBRA treatment strategy in early rheumatoid arthritis? (2007) (45)
The validity of pooled outcome measures (indices) in rheumatoid arthritis clinical trials. (1993) (44)
Rheumatoid factor measured by fluoroimmunoassay: a responsive measure of rheumatoid arthritis disease activity that is associated with joint damage (2002) (44)
Can We Decide Which Outcomes Should Be Measured in Every Clinical Trial? A Scoping Review of the Existing Conceptual Frameworks and Processes to Develop Core Outcome Sets (2014) (44)
Reversible nephrotoxicity of cyclosporine in rheumatoid arthritis. (1990) (43)
Add-on or step-up trials for new drug development in rheumatoid arthritis: a new standard? (2003) (43)
A method for achieving consensus on rheumatoid arthritis outcome measures: the OMERACT conference process. (1993) (43)
Validity and measurement precision of the PROMIS physical function item bank and a content validity-driven 20-item short form in rheumatoid arthritis compared with traditional measures. (2015) (43)
Chronological reading of radiographs in rheumatoid arthritis increases efficiency and does not lead to bias (2013) (42)
Computer based methods for measurement of joint space width: update of an ongoing OMERACT project. (2007) (42)
How well are the ASAS/OMERACT Core Outcome Sets for Ankylosing Spondylitis implemented in randomized clinical trials? A systematic literature review (2014) (42)
Aggressive therapy in patients with early arthritis results in similar outcome compared with conventional care: the STREAM randomized trial (2011) (42)
“Official View” on Glucocorticoids in Rheumatoid Arthritis: A Systematic Review of International Guidelines and Consensus Statements (2017) (41)
Scope for improvement in the quality of reporting of systematic reviews. From the Cochrane Musculoskeletal Group. (2006) (41)
Proposal for Levels of Evidence Schema for Validation of a Soluble Biomarker Reflecting Damage Endpoints in Rheumatoid Arthritis, Psoriatic Arthritis, and Ankylosing Spondylitis, and Recommendations for Study Design (2009) (41)
Use of the American College of Rheumatology N (ACR-N) index of improvement in rheumatoid arthritis: argument in opposition. (2005) (41)
Longterm cyclosporine therapy in rheumatoid arthritis. (1991) (41)
Subclinical synovitis detected by macrophage PET, but not MRI, is related to short-term flare of clinical disease activity in early RA patients: an exploratory study (2015) (40)
At what age could screening for familial retinoblastoma be stopped? A register based study 1945–98 (2000) (40)
Circulating microparticles remain associated with complement activation despite intensive anti-inflammatory therapy in early rheumatoid arthritis (2009) (40)
Successful Stepwise Development of Patient Research Partnership: 14 Years’ Experience of Actions and Consequences in Outcome Measures in Rheumatology (OMERACT) (2016) (40)
Toward a Generalized Framework of Core Measurement Areas in Clinical Trials: A Position Paper for OMERACT 11 (2014) (40)
Adverse events after first COVID-19 vaccination in patients with autoimmune diseases (2021) (40)
Balneotherapy for osteoarthritis. A cochrane review. (2008) (39)
Patient Perspective on Remission in Rheumatoid Arthritis (2011) (39)
COST-EFFECTIVENESS AND COST-UTILITY OF COMBINATION THERAPY IN EARLY RHEUMATOID ARTHRITIS : RANDOMIZED COMPARISON OF COMBINED STEP-DOWN PREDNISOLONE , METHOTREXATE AND SULPHASALAZINE WITH SULPHASALAZINE ALONE (1998) (39)
Robustness and generalizability of smallest detectable difference in radiological progression. (2001) (39)
Combination DMARD therapy including corticosteroids in early rheumatoid arthritis. (1999) (39)
Evidence on the measurement properties of health-related quality of life instruments is largely missing in patients with low back pain: A systematic review. (2018) (39)
Measures to assess ankylosing spondylitis: taxonomy, review and recommendations. (1993) (38)
Development of EULAR recommendations for the reporting of clinical trial extension studies in rheumatology (2014) (38)
Recruitment and Retention of Older People in Clinical Research: A Systematic Literature Review (2020) (37)
MCID/Low Disease Activity State Workshop: low disease activity state in rheumatoid arthritis. (2003) (37)
Patient-reported outcomes in core domain sets for rheumatic diseases (2015) (37)
The Sharp/van der Heijde method out-performed the Larsen/Scott method on the individual patient level in assessing radiographs in early rheumatoid arthritis. (2004) (37)
Updating the OMERACT Filter: Implications of Filter 2.0 to Select Outcome Instruments Through Assessment of “Truth”: Content, Face, and Construct Validity (2014) (36)
Patients with rheumatic diseases adhere to COVID-19 isolation measures more strictly than the general population (2020) (36)
Indirect and total costs of early rheumatoid arthritis: a randomized comparison of combined step-down prednisolone, methotrexate, and sulfasalazine with sulfasalazine alone. (2001) (36)
Decreasing incidence of symptomatic gastrointestinal ulcers and ulcer complications in patients with rheumatoid arthritis (2007) (36)
Renal disorders in rheumatoid arthritis. (1990) (35)
Quantitative Radiographic Features of Early Knee Osteoarthritis: Development Over 5 Years and Relationship with Symptoms in the CHECK Cohort (2013) (35)
MCID/Low Disease Activity State Workshop: summary, recommendations, and research agenda. (2003) (35)
Subclinical renal dysfunction is independently associated with cardiovascular events in rheumatoid arthritis: the CARRÉ Study (2011) (35)
The responsiveness of generic quality of life instruments in rheumatic diseases. A systematic review of randomized controlled trials. (1999) (34)
Trilateral retinoblastoma: is the location of the intracranial tumor important? (2000) (34)
Effect of nonsteroidal antiinflammatory drugs on the C-reactive protein level in rheumatoid arthritis: a meta-analysis of randomized controlled trials. (2012) (33)
A reference case for economic evaluations in osteoarthritis: an expert consensus article from the European Society for Clinical and Economic Aspects of Osteoporosis and Osteoarthritis (ESCEO). (2014) (33)
Dynamics of circulating TNF during adalimumab treatment using a drug-tolerant TNF assay (2019) (33)
The Use of Placebo-Controlled and Non-inferiority Trials for the Evaluation of New Drugs in the Treatment of Postmenopausal Osteoporosis (2002) (33)
Harm, benefit and costs associated with low-dose glucocorticoids added to the treatment strategies for rheumatoid arthritis in elderly patients (GLORIA trial): study protocol for a randomised controlled trial (2018) (33)
Calibration and Validation of the Dutch-Flemish PROMIS Pain Interference Item Bank in Patients with Chronic Pain (2015) (33)
Cardiovascular risk management in rheumatoid arthritis patients still suboptimal: the Implementation of Cardiovascular Risk Management in Rheumatoid Arthritis project (2017) (32)
The case for corticosteroids in the treatment of early rheumatoid arthritis. (1999) (32)
Current Status of Outcome Measure Development in Vasculitis (2014) (32)
Remission in early rheumatoid arthritis defined by 28 joint counts: limited consequences of residual disease activity in the forefeet on outcome (2011) (32)
Progress Towards a Core Set of Outcome Measures in Small-vessel Vasculitis. Report from OMERACT 9 (2009) (32)
Development of draft validation criteria for a soluble biomarker to be regarded as a valid biomarker reflecting structural damage endpoints in rheumatoid arthritis and spondyloarthritis clinical trials. (2007) (31)
Chemoreduction for retinoblastoma. (2003) (31)
Calibration of the PROMIS Physical Function Item Bank in Dutch Patients with Rheumatoid Arthritis (2014) (31)
Reproducibility and clinical value of 18F-fluorodeoxyglucose positron emission tomography in recurrent melanoma (2002) (31)
Detection of Subclinical Synovitis with Macrophage Targeting and Positron Emission Tomography in Patients with Rheumatoid Arthritis without Clinical Arthritis (2014) (30)
Report of the OMERACT task force on economic evaluation. Outcome Measures in Rheumatology. (1999) (30)
Graphics and statistics for cardiology: designing effective tables for presentation and publication (2017) (30)
Reduced joint counts in rheumatoid arthritis clinical trials. American College of Rheumatology Committee on Outcome Measures in Rheumatoid Arthritis Clinical Trials. (1994) (30)
Defining the optimal biological monotherapy in rheumatoid arthritis: A systematic review and meta-analysis of randomised trials. (2017) (30)
Is it time to revisit the role of ultrasound in rheumatoid arthritis management? (2016) (29)
14-3-3η Autoantibodies: Diagnostic Use in Early Rheumatoid Arthritis (2015) (29)
An updated review of glucocorticoid-related adverse events in patients with rheumatoid arthritis (2019) (28)
A Delphi Exercise to Identify Characteristic Features of Gout — Opinions from Patients and Physicians, the First Stage in Developing New Classification Criteria (2013) (28)
Comparison of interferon-{gamma} release assays and tuberculin skin test in predicting active tuberculosis (TB) in children in the UK: a paediatric TB network study (2010) (28)
A New Concept of Health Can Improve the Definition of Frailty (2015) (28)
Bone turnover, joint damage and bone mineral density in early rheumatoid arthritis treated with combination therapy including high-dose prednisolone. (2001) (28)
Patient's global assessment of disease activity: what are we measuring? (2012) (27)
The Dutch-Flemish PROMIS Physical Function item bank exhibited strong psychometric properties in patients with chronic pain. (2017) (27)
Wrist splints in rheumatoid arthritis: A question of belief? (1994) (27)
Normal mortality of the COBRA early rheumatoid arthritis trial cohort after 23 years of follow-up (2018) (27)
Low disease activity state in rheumatoid arthritis: concepts and derivation of minimal disease activity. (2006) (27)
The OMERACT-ICF Reference Group: Integrating the ICF into the OMERACT Process: Opportunities and Challenges (2009) (27)
IMPACT OF QUALITY ITEMS ON STUDY OUTCOME (2000) (27)
Costs of treating bleeding and perforated peptic ulcers in The Netherlands. (2004) (27)
Validation of two PROMIS item banks for measuring social participation in the Dutch general population (2018) (27)
Measurement of stiffness in patients with rheumatoid arthritis in low disease activity or remission: a systematic review (2014) (27)
OMERACT Endorsement of Measures of Outcome for Studies of Acute Gout (2014) (26)
A first step to assess harm and benefit in clinical trials in one scale. (2010) (26)
Assessing the activity of rheumatoid arthritis. (1995) (26)
Use and effects of custom-made therapeutic footwear on lower-extremity-related pain and activity limitations in patients with rheumatoid arthritis: A prospective observational study of a cohort. (2014) (26)
Clinical trials of new drugs for the treatment of rheumatoid arthritis: focus on early disease (2016) (26)
Comparative risk of malignancies and infections in patients with rheumatoid arthritis initiating abatacept versus other biologics: a multi-database real-world study (2019) (24)
Errors in the prediction of creatinine clearance in patients with rheumatoid arthritis. (1988) (24)
Serum Urate in Chronic Gout — Will It Be the First Validated Soluble Biomarker in Rheumatology? (2011) (24)
Effectiveness of an (18)F-FDG-PET based strategy to optimize the diagnostic trajectory of suspected recurrent laryngeal carcinoma after radiotherapy: The RELAPS multicenter randomized trial. (2016) (24)
Development of a Provisional Core Domain Set for Polymyalgia Rheumatica: Report from the OMERACT 12 Polymyalgia Rheumatica Working Group (2016) (23)
Cardiovascular Event Risk in Rheumatoid Arthritis Compared with Type 2 Diabetes: A 15-year Longitudinal Study (2019) (23)
Testing of the OMERACT 8 Draft Validation Criteria for a Soluble Biomarker Reflecting Structural Damage in Rheumatoid Arthritis: A Systematic Literature Search on 5 Candidate Biomarkers (2009) (23)
Feasibility of Self-Monitoring Rheumatoid Arthritis With a Smartphone App: Results of Two Mixed-Methods Pilot Studies (2020) (23)
Remission in Rheumatoid Arthritis: Physician and Patient Perspectives (2009) (23)
Exploration, Development, and Validation of Patient-reported Outcomes in Antineutrophil Cytoplasmic Antibody–associated Vasculitis Using the OMERACT Process (2015) (23)
Methods of deriving EULAR/ACR recommendations on reporting disease activity in clinical trials of patients with rheumatoid arthritis (2008) (23)
Screening for pineoblastoma in patients with retinoblastoma. (2002) (23)
Breakthrough SARS-CoV-2 infections with the delta (B.1.617.2) variant in vaccinated patients with immune-mediated inflammatory diseases using immunosuppressants: a substudy of two prospective cohort studies (2022) (23)
Minimal clinically important difference in plain films in RA: group discussions, conclusions, and recommendations. OMERACT Imaging Task Force. (2001) (23)
Updating the OMERACT Filter at OMERACT 11 (2014) (22)
Wrist splints in rheumatoid arthritis: what do we know about efficacy and compliance? (1994) (22)
How to interpret radiological progression in randomized clinical trials? (2003) (22)
Demonstration of response in rheumatoid arthritis patients who are nonresponders according to the American College of Rheumatology 20% criteria: the paradox of beneficial treatment effects in nonresponders in the ATTRACT trial. Anti-Tumor Necrosis Factor Trial in Rheumatoid Arthritis with Concomitan (2001) (22)
Updating the OMERACT Filter: Core Areas as a Basis for Defining Core Outcome Sets (2014) (22)
The OMERACT Stepwise Approach to Select and Develop Imaging Outcome Measurement Instruments: The Musculoskeletal Ultrasound Example (2019) (22)
Remission in Rheumatoid Arthritis: Working Toward Incorporation of the Patient Perspective at OMERACT 12 (2016) (22)
Assessing single joints in arthritis clinical trials. (2007) (22)
THE INFLUENCE OF METHODOLOGIC QUALITY ON THE CONCLUSION OF A LANDMARK META-ANALYSIS ON THROMBOLYTIC THERAPY (2002) (21)
A practical exercise in reading RA radiographs by the larsen and sharp methods. (1999) (21)
Fluorine-18 fluorodeoxyglucose positron emission tomography (PET) to detect vital retinoblastoma in the eye: Preliminary experience (2004) (21)
Endpoints in rheumatoid arthritis. (1994) (21)
Automated measurement of joint space width in small joints of patients with rheumatoid arthritis. (2008) (20)
The selective estrogen receptor alpha agonist Org 37663 induces estrogenic effects but lacks antirheumatic activity: a phase IIa trial investigating efficacy and safety of Org 37663 in postmenopausal female rheumatoid arthritis patients receiving stable background methotrexate or sulfasalazine. (2010) (20)
Update on outcome assessment in rheumatic disorders (2000) (20)
Testing of the preliminary OMERACT validation criteria for a biomarker to be regarded as reflecting structural damage endpoints in rheumatoid arthritis clinical trials: the example of C-reactive protein. (2007) (20)
A randomized trial of PET scanning to improve diagnostic yield of direct laryngoscopy in patients with suspicion of recurrent laryngeal carcinoma after radiotherapy. (2007) (20)
Updating the OMERACT Filter: Discrimination and Feasibility (2014) (20)
Hexokinase III, cyclin A and galectin‐3 are overexpressed in malignant follicular thyroid nodules (2008) (20)
An Algorithm for the Diagnosis of Behçet Disease Uveitis in Adults (2020) (20)
Updating the OMERACT Filter: Implications for Imaging and Soluble Biomarkers (2014) (20)
A simple model that suggests possible cost savings when modified-release prednisone 5 mg/day is added to current treatment in patients with active rheumatoid arthritis. (2013) (20)
Imaging in rheumatoid arthritis: results of group discussions. (1999) (20)
Domains Selection for Patient-Reported Outcomes: Current Activities and Options for Future Methods (2011) (19)
Development and Preliminary Testing of a Computerized Animated Activity Questionnaire in Patients With Hip and Knee Osteoarthritis (2015) (19)
Delphi process yielded consensus on terminology and research agenda for therapeutic footwear for neuropathic foot. (2008) (19)
Toward less futile surgery in non-small cell lung cancer? A randomized clinical trial to evaluate the cost-effectiveness of positron emission tomography. (2001) (19)
Atorvastatin is unlikely to prevent rheumatoid arthritis in high risk individuals: results from the prematurely stopped STAtins to Prevent Rheumatoid Arthritis (STAPRA) trial (2021) (19)
Recommended core outcome instruments for health-related quality of life, long-term control and itch intensity in atopic eczema trials: results of the HOME VII consensus meeting. (2020) (19)
Studying the benefit/risk ratio of glucocorticoids in rheumatoid arthritis. (2007) (19)
Meta-analysis suggests that intensive non-biological combination therapy with step-down prednisolone (COBRA strategy) may also ‘disconnect’ disease activity and damage in rheumatoid arthritis (2012) (19)
Health status instruments / utilities. (1995) (19)
Recommended core outcome instruments for health‐related quality of life, long‐term control and itch intensity in atopic eczema trials: results of the HOME VII consensus meeting (2021) (19)
High dose chemotherapy followed by autologous peripheral blood stem cell transplantation or conventional pharmacological treatment for refractory rheumatoid arthritis? A Markov decision analysis. (2001) (18)
Calibration of the Dutch‐Flemish PROMIS Pain Behavior item bank in patients with chronic pain (2016) (18)
Outcome measures for adherence data from a medication event monitoring system: A literature review (2018) (18)
Posttraumatic stress in aging World War II survivors after a fireworks disaster: a controlled prospective study. (2006) (18)
Low dose, add-on prednisolone in patients with rheumatoid arthritis aged 65+: the pragmatic randomised, double-blind placebo-controlled GLORIA trial (2022) (17)
Helicobacter pylori Eradication in Patients on Long-term Treatment With NSAIDs Reduces the Severity of Gastritis: A Randomized Controlled Trial (2009) (17)
Similar efficacy and safety of initial COBRA-light and COBRA therapy in rheumatoid arthritis: 4-year results from the COBRA-light trial (2017) (17)
EULAR recommendations for the reporting of ultrasound studies in rheumatic and musculoskeletal diseases (RMDs) (2021) (17)
Standardized assessment of adverse events in rheumatology clinical trials: summary of the OMERACT 7 drug safety module update. (2005) (16)
Updated Consolidated Standards of Reporting Trials (CONSORT): it just gets better. (2010) (16)
Consensus on the Need for a Hierarchical List of Patient-reported Pain Outcomes for Metaanalyses of Knee Osteoarthritis Trials: An OMERACT Objective (2015) (16)
Zoledronate in the prevention of Paget’s (ZiPP): protocol for a randomised trial of genetic testing and targeted zoledronic acid therapy to prevent SQSTM1-mediated Paget’s disease of bone (2019) (16)
Rheumatoid arthritis: Remission — keeping the patient experience front and centre (2017) (16)
Uptake of the OMERACT-OARSI Hip and Knee Osteoarthritis Core Outcome Set: Review of Randomized Controlled Trials from 1997 to 2017 (2019) (15)
Examining the Similarities and Differences of OMERACT Core Sets Using the ICF: First Step Towards an Improved Domain Specification and Development of an Item Pool to Measure Functioning and Health (2011) (15)
Abatacept in Rheumatoid Arthritis: A New Branch on the Biologics Tree (2006) (15)
No effect of misoprostol on renal function of rheumatoid patients treated with diclofenac. (1991) (15)
A Smartphone App for Self-Monitoring of Rheumatoid Arthritis Disease Activity to Assist Patient-Initiated Care: Protocol for a Randomized Controlled Trial (2019) (15)
Cost-Effectiveness of Biologics as First-Line Treatment of Rheumatoid Arthritis: Case Closed? (2009) (15)
Glucocorticoids in rheumatoid arthritis: a senescent research agenda on the brink of rejuvenation? (2004) (15)
Discontinuation of Vioxx. Authors' reply (2005) (15)
Assessment of health outcomes (2009) (15)
Deriving an operational definition of low disease activity state in rheumatoid arthritis. (2003) (15)
Serum creatinine levels two years later: follow-up of a placebo-controlled trial of cyclosporine in rheumatoid patients. (1988) (15)
OMERACT conference questionnaire results. OMERACT Committee. (1993) (15)
Seminal pharmaceutical trials: maintaining masking in analysis (2002) (14)
Quality Assessment of Trials: A Comparison of Three Criteria Lists (2000) (14)
High incidence of cardiovascular events in patients with rheumatoid arthritis (2009) (14)
What Is the Relationship Between Morning Symptoms and Measures of Disease Activity in Patients With Rheumatoid Arthritis? (2015) (14)
[Combination therapy in early rheumatoid arthritis: the COBRA study]. (1997) (14)
Balneotherapy (or spa therapy) for rheumatoid arthritis. An abridged version of Cochrane Systematic Review. (2015) (14)
One-year effects of glucocorticoids on bone density: a meta-analysis in cohorts on high and low-dose therapy (2016) (14)
A new design for registration trials in rheumatoid arthritis allowing secondary head-to-head comparisons with standard of care treatment including biologicals (2009) (14)
The validity of radiography as outcome measure in rheumatoid arthritis. (1995) (13)
OMERACT 9 ‒ 9th International Consensus Conference on Outcome Measures in Rheumatology Clinical Trials (2009) (13)
OMERACT 9 ‒ 9th International Consensus Conference on Outcome Measures in Rheumatology Clinical Trials (2009) (13)
An unfavorable body composition is common in early arthritis patients: A case control study (2018) (13)
Minimal Clinically Important Difference in Plain Films in RA : Group Discussions , Conclusions , and Recommendations (2002) (13)
Recommendations for an update of 2003 European regulatory requirements for registration of drugs to be used in the treatment of RA (2011) (13)
Applicability of trials in rheumatoid arthritis and osteoarthritis: A systematic review and meta-analysis of trial populations showing adequate proportion of women, but underrepresentation of elderly people. (2019) (13)
Contribution of progression of erosive damage in previously eroded joints in early rheumatoid arthritis trials: COBRA trial as an example. (2002) (12)
Does sex of rheumatoid arthritis patients matter? (1998) (12)
Cyclosporine nephrotoxicity in rheumatoid arthritis: no effect of short term misoprostol treatment. (1992) (12)
OMERACT 5 Economics Working Group: summary, recommendations, and research agenda. (2001) (12)
Standing on the promises: first wave validation reports of the Patient-Reported Outcome Measurement Information System. (2010) (12)
Recent rheumatoid arthritis clinical trials using radiographic endpoints--updated research agenda. (2001) (12)
First Validation of the Full PROMIS Pain Interference and Pain Behavior Item Banks in Patients With Rheumatoid Arthritis (2020) (12)
Smartphone‐Assisted Patient‐Initiated Care Versus Usual Care in Patients With Rheumatoid Arthritis and Low Disease Activity: A Randomized Controlled Trial (2022) (12)
Cost Effectiveness and Cost Utility of Acetylcysteine versus Dimethyl Sulfoxide for Reflex Sympathetic Dystrophy (2012) (12)
Time to review policy on contraindications to vaccination (2000) (12)
Considerations and preliminary proposals for defining a reference case for economic evaluations in ankylosing spondylitis. (2007) (12)
The short-term effects of two high-dose, step-down prednisolone regimens on body composition in early rheumatoid arthritis. (2016) (12)
Raised plasma renin and prorenin in rheumatoid vasculitis. (1990) (12)
Suboptimal cardiovascular risk management in rheumatoid arthritis patients despite an explicit cardiovascular risk screening programme (2019) (11)
Rationale and design of The Delphi Trial – I(RCT)2: international randomized clinical trial of rheumatoid craniocervical treatment, an intervention-prognostic trial comparing 'early' surgery with conservative treatment [ISRCTN65076841] (2006) (11)
Validating Rheumatoid Arthritis Remission Using the Patients’ Perspective: Results from a Special Interest Group at OMERACT 2016 (2017) (11)
RAID: a valid tool to quantify the impact of rheumatoid arthritis. But what impact will it have on the core set for trials? (2011) (11)
Rationale and strategies for reevaluating the ACR20. (2007) (11)
The time has come to limit the placebo period in rheumatoid arthritis trials to 3 months: a systematic comparison of 3- and 6-month response rates in trials of biological agents (2009) (11)
Missing data in trials: do we have to keep carrying the last observation forward? (2008) (11)
Multiple Computer-based Methods of Measuring Joint Space Width Can Discriminate Between Treatment Arms in the COBRA Trial — Update of an Ongoing OMERACT Project (2009) (11)
Towards developing diagnostic criteria for early knee osteoarthritis: data from the CHECK study (2020) (11)
The HOME Core outcome set for clinical trials of atopic dermatitis. (2022) (10)
The COBRA trial 20 years later. (2011) (10)
Risk of Biologics and Glucocorticoids in Patients With Rheumatoid Arthritis Undergoing Arthroplasty (2019) (10)
Prediction of glomerular filtration rate in patients with rheumatoid arthritis: satisfactory performance of Cockroft formula. (1994) (10)
Effective Treatment for Rapid Improvement of Both Disease Activity and Self‐Reported Physical Activity in Early Rheumatoid Arthritis (2016) (10)
Patient based methods for assessing adverse events in clinical trials in rheumatology. Progress report for the OMERACT Drug Toxicity Working Party. Outcome Measures in Rheumatology. (1999) (10)
Developing an OMERACT Core Outcome Set for Assessing Safety Components in Rheumatology Trials: The OMERACT Safety Working Group (2017) (10)
Observational studies on glucocorticoids are harmful! (2017) (10)
Syk kinase inhibitors for rheumatoid arthritis: trials and tribulations. (2011) (10)
Outcome measures in rheumatoid arthritis: the OMERACT process (2007) (9)
Introduction - OMERACT IV: Fourth International Consensus Conference on Outcome Measures in Rheumatology (1999) (9)
Patient global assessment to define remission in rheumatoid arthritis:quo vadis? (2020) (9)
Biological treatment in rheumatoid arthritis: when to stop? (2014) (9)
How to Ascertain Drug Safety in the Context of Benefit. Controversies and Concerns (2009) (9)
Barriers and potential solutions in the recruitment and retention of older patients in clinical trials-lessons learned from six large multicentre randomized controlled trials. (2021) (9)
Relapse-remission and remission-relapse switches in rheumatoid arthritis patients were modeled by random effects. (2009) (9)
Null bar and null zone are better than the error bar to compare group means in graphs. (2004) (9)
Identifying Provisional Generic Contextual Factor Domains for Clinical Trials in Rheumatology: Results from an OMERACT Initiative (2019) (9)
EULAR Points to Consider (PtC) for designing, analysing and reporting of studies with work participation as an outcome domain in patients with inflammatory arthritis (2021) (9)
Facilitating the Use of COBRA Combination Therapy in Early Rheumatoid Arthritis: A Pilot Implementation Study (2009) (8)
Safety of Abatacept Versus Placebo in Rheumatoid Arthritis: Integrated Data Analysis of Nine Clinical Trials (2019) (8)
Low dose prednisolone for treatment of RA. (2004) (8)
American College of Rheumatology treatment guidelines continue to omit guidance on glucocorticoids: Comment on the article by Singh et al (2012) (8)
Assessing the effect of interventions for axial spondyloarthritis according to the endorsed ASAS/OMERACT core outcome set: a meta-research study of trials included in Cochrane reviews (2020) (8)
Short and sustained periods of ACR/EULAR remission predict good functional outcome, but do not predict good radiographic outcome in early rheumatoid arthritis patients with low overall damage progression. (2016) (8)
Patients' and rheumatologists' perspectives on the efficacy and safety of low-dose glucocorticoids in rheumatoid arthritis-an international survey within the GLORIA study. (2021) (8)
Content validity of the Dutch Rheumatoid Arthritis Impact of Disease (RAID) score: results of focus group discussions in established rheumatoid arthritis patients and comparison with the International Classification of Functioning, Disability and Health core set for rheumatoid arthritis (2016) (8)
A new graph and scoring system simplified analysis of changing states: disease remissions in a rheumatoid arthritis clinical trial. (2010) (8)
Cross‐Cultural and Construct Validity of the Animated Activity Questionnaire (2017) (8)
Patient based method of assessing adverse events in clinical trials in rheumatology: the revised Stanford Toxicity Index. (2001) (8)
Do we need randomised trials to evaluate diagnostic procedures? (2003) (8)
Designing effective graphs to get your message across (2018) (8)
Considerations and priorities for incorporating the patient perspective on remission in rheumatoid arthritis: An OMERACT 2020 special interest group report. (2021) (7)
Drugs and cardiovascular risk in inflammatory arthritis: another case of glucocorticoid-bashing? (2015) (7)
Immunohistochemical analysis of vascular endothelial growth factor expression in severe and destructive rheumatoid arthritis. (2000) (7)
Serum levels of receptor activator of nuclear factor kappa-beta (RANK)-ligand (L) and osteoprotegerin (OPG) independently predict long-term radiographic progression in patients with early rheumatoid arthritis (RA) (2003) (7)
Combined effect size: comment on the metaanalysis of second-line drugs in rheumatoid arthritis. (1991) (7)
THU0244 14-3-3Eta is an Independent Predictor of Radiographic Changes in Early RA and Higher Titres Inform A Higher Likelihood of Joint Damage Progression (2014) (7)
Systematic review of the cost effectiveness of prophylactic treatments in the prevention of gastropathy in patients with rheumatoid arthritis or osteoarthritis taking non-steroidal anti-inflammatory drugs (2000) (7)
IgM-rheumatoid factor and anti-cyclic citrullinated peptide decrease by 50% during intensive treatment in early rheumatoid arthritis (2009) (7)
Investigating the Validity of the Minimal Disease Activity State for Patients with Rheumatoid Arthritis Treated with Abatacept (2009) (7)
PROMIS Physical Function short forms display item- and scale-level characteristics at least as good as the Roland Morris Disability Questionnaire in patients with chronic low back pain. (2020) (7)
Observations from the OMERACT Drug Safety Summit, May 2008 (2009) (7)
COVID-19 vaccine acceptance over time in patients with immune-mediated inflammatory rheumatic diseases (2022) (7)
Pathophysiology of rheumatoid arthritis: split or lump? (2008) (7)
Progress toward the development of a new definition of remission in rheumatoid arthritis. (2010) (7)
A Delphi Exercise to Identify Characteristic Features of Gout — Opinions from Patients and Physicians, the First Stage in Developing New Classification Criteria (2013) (7)
Short-term placebo response in trials of patients with symptomatic osteoarthritis: differences between hip and knee. (2016) (7)
Non-overlapping American College of Rheumatology response rates: a better way to report response in rheumatoid arthritis clinical trials. (2010) (7)
Inclusion of glucocorticoids in recommendations for the use of nonbiologic and biologic disease-modifying antirheumatic drugs in rheumatoid arthritis: Comment on the article by Saag et al. (2008) (6)
Achieving consensus on minimum data items (including core outcome domains) for a longitudinal observational cohort study in rheumatoid arthritis (2016) (6)
Response to: ‘Let's not fool ourselves. In RA, the ACR/EULAR remission criteria are not perfect!’ by Baker et al (2016) (6)
Do Short and Sustained Periods of American College of Rheumatology/European League Against Rheumatism Remission Predict Functional and Radiographic Outcome in Early Rheumatoid Arthritis Patients With Low Overall Damage Progression? (2017) (6)
A call for pragmatic treatment trials in rheumatoid arthritis (2008) (6)
Prevention or Retardation of Joint Damage in Rheumatoid Arthritis (2012) (6)
Higher body mass index is associated with lower foot health in patients with rheumatoid arthritis: baseline results of the Amsterdam-Foot cohort (2020) (6)
Feasibility and Face Validity of Outcome Measures for Use in Future Studies of Polymyalgia Rheumatica: An OMERACT Study (2020) (6)
Optimising both disease control and glucocorticoid dosing is essential for bone protection in patients with rheumatic disease (2022) (6)
OP0151 Cobra-light therapy is clinically non-inferior to original cobra therapy in the treatment of early rheumatoid arthritis (2013) (6)
Predictors of sick leave and improved worker productivity after 52 weeks of intensive treatment in patients with early rheumatoid arthritis (2019) (6)
Dutch reference values for the Patient-Reported Outcomes Measurement Information System Scale v1.2 - Global Health (PROMIS-GH) (2021) (6)
Antibody development and disease severity of COVID-19 in non-immunised patients with rheumatic immune-mediated inflammatory diseases: data from a prospective cohort study (2022) (6)
The controversy of using PGA to define remission in RA (2018) (6)
The need for Health Technology Assessments of PET (2003) (6)
Erratum to: Core outcome domains for clinical trials in non-specific low back pain (2015) (6)
The evolution of instrument selection for inclusion in core outcome sets at OMERACT: Filter 2.2. (2021) (5)
The cost-utility analysis of the BeSt trial: is a camel in fact a horse with abnormalities in the distribution of dorsal fat? Comment on the article by van den Hout et al. (2009) (5)
Erratum to: Recommendations for the Health Economics Analysis to be Performed with a Drug to be Registered in Prevention or Treatment of Osteoporosis (1998) (5)
256 CHECK: COHORT HIP AND COHORT KNEE; SIMILARITIES AND DIFFERENCES WITH THE OA INITIATIVE (2008) (5)
Low-dose prednisone in rheumatoid arthritis patients: placebo treatment? (1991) (5)
Let’s stop fooling ourselves. In RA, only ACR/EULAR criteria define remission and equate with absence of disease! (2016) (5)
Towards consensus in defining and handling contextual factors within rheumatology trials: an initial qualitative study from an OMERACT working group (2020) (5)
OMERACT consensus-based operational definition of contextual factors in rheumatology clinical trials: A mixed methods study. (2021) (5)
Glucocorticoid Effect on Radiographic Progression in Placebo Arms of Rheumatoid Arthritis Biologics Trials (2016) (5)
Effect of the Application of Trial Inclusion Criteria on the Efficacy of Adalimumab Therapy in a Rheumatoid Arthritis Cohort (2011) (5)
SAT0037 Serum 14-3-3Eta Predicts the Risk of RA Development and Its Higher Titres Are Associated with Higher Risk (2014) (5)
Cost-utility of COBRA-light versus COBRA therapy in patients with early rheumatoid arthritis: the COBRA-light trial (2017) (5)
International consensus on which measures to use in rheumatoid arthritis clinical trials. (1993) (5)
Adaptive Trial Designs in Rheumatology: Report from the OMERACT Special Interest Group (2019) (5)
Improving domain definition and outcome instrument selection: Lessons learned for OMERACT from imaging. (2021) (5)
Medication adherence in older people with rheumatoid arthritis is lower according to electronic monitoring than according to pill count (2021) (5)
Can progression of radiographic joint damage be predicted early in rheumatoid arthritis? (2003) (5)
Further Simplification of the Simple Erosion Narrowing Score With Item Response Theory Methodology (2016) (5)
Identifying Possible Outcome Domains from Existing Outcome Measures to Inform an OMERACT Core Domain Set for Safety in Rheumatology Trials (2019) (5)
Diagnostic criteria for early hip osteoarthritis: first steps, based on the CHECK study (2021) (4)
Combination therapy in rheumatoid arthritis (1999) (4)
Serum dehydroepiandrosterone sulphate levels in patients with early rheumatoid arthritis: positive association with C-reactive protein, but not with HLA-DR genotype. (1998) (4)
Rheumatoid arthritis as important independent risk factor for incident cardiovascular disease (2008) (4)
Patient-Reported Pain is Central to OMERACT Rheumatology Core Measurement Sets (2006) (4)
SARS-CoV-2 breakthrough infections in patients with immune-mediated inflammatory diseases during the omicron dominant period (2022) (4)
Value of magnetic resonance imaging in rheumatoid arthritis? (2000) (4)
EMEA guidelines for trials in osteoporosis: design implications. (2002) (4)
Prevalence and validity of ACR/EULAR remission in four European early rheumatoid arthritis cohorts. (2018) (4)
American College of Rheumatology criteria for improvement in rheumatoid arthritis should only be calculated from scores that decrease on improvement. (2001) (4)
FRI0553 “back to being normal”: the patient perspective on remission in rheumatoid arthritis (2013) (4)
The benefit of low-dose glucocorticoid treatment in early rheumatoid arthritis may outweigh the risk: comment on the editorial by Harris. (2006) (4)
33 – Assessment of Health Outcomes (2013) (4)
Population characteristics as important contextual factors in rheumatological trials: an exploratory meta-epidemiological study from an OMERACT Working Group (2020) (4)
Chapter 33 – Assessment of Health Outcomes (2017) (4)
Percutaneous coronary intervention with off-site cardiac surgical backup. (2008) (4)
Updating the 2003 European regulatory requirements for registering disease-modifying drugs to be used in the treatment of rheumatoid arthritis. (2011) (3)
Recommendations for the Health Economics Analysis to be Performed with a Drug to be Registered in Prevention or Treatment of Osteoporosis (2013) (3)
OMERACT 10 — International Consensus Conference on Outcome Measures in Rheumatology Clinical Trials (2011) (3)
Patient-reported Remission in Rheumatoid Arthritis (2013) (3)
Predicting outcome of ankylosing spondylitis: prognosis or hindsight? (1994) (3)
SAT0189 Dynamics of circulating tnf during adalimumab treatment of rheumatoid arthritis using a novel drug-tolerant tnf assay (2018) (3)
THU0154 Adverse effects of glucocorticoid therapy in rheumatoid arthritis (RA): A systematic review and meta-analysis of randomized controlled trials (2013) (3)
Recent Developments for Optimal End-Points in Rheumatoid Arthritis Clinical Studies (2000) (3)
Reliability of spot samples for assessment of urinary excretion of pyridinoline in patients with rheumatoid arthritis. (2001) (3)
OP0276 Risk of Serious Adverse Effects Associated with Different Biological and Targeted Synthetic Disease-Modifying Anti-Rheumatic Drugs in Patients with Rheumatoid Arthritis: A Systematic Review and Meta-Analysis of Randomised Trials (2015) (3)
Initial High-Dose Prednisolone Combination Therapy Using COBRA and COBRA-Light in Early Rheumatoid Arthritis (2014) (3)
Fake good test-taking attitude in ankylosing-spondylitis (1992) (3)
Eradication of Helicobacter pylori does not reduce the incidence of gastroduodenal ulcers in patients on long-term NSAID treatment: A randomized, double blind placebo controlled trial (2004) (3)
OP0226 SOLID TUMOUR OUTCOMES IN PATIENTS WITH RA TREATED WITH ABATACEPT AND OTHER DMARDS: RESULTS FROM A 10-YEAR INTERNATIONAL POST-APPROVAL STUDY (2019) (3)
The implementation of PET in non-small-cell lung cancer in the Netherlands. (2006) (3)
DISEASE-MODIFYING DRUGS SERIES EDITOR: T. PULLAR COMBINATION THERAPY IN RHEUMATOID ARTHRITIS: UPDATED SYSTEMATIC REVIEW (1998) (2)
The RAPID3 questionnaire as a screening tool to reduce the number of outpatient clinic visits: a retrospective cohort study (2022) (2)
Penetration of cyclosporin into synovial fluid in rheumatoid arthritis (2004) (2)
Has the rheumatoid arthritis (RA) core outcome set influenced the selection of study outcome measures? (2013) (2)
Long-term effects on bone mineral density after four years of treatment with two intensive combination strategies, including initially high-dose prednisolone, in early rheumatoid arthritis patients: the COBRA-light trial (2021) (2)
Eradication of Helicobacter pylori does not reduce the incidence of gastroduodenal ulcers in patients on long-term NSAID- treatment - A randomized, placebo controlled trial. (2004) (2)
Methodology of combination trials (2001) (2)
[The value of roentgen pictures in rheumatoid arthritis]. (1997) (2)
A framework to classify burden of illness measures. (1995) (2)
Paradoxically protective effect of glucocorticoids on bone mass and fragility fracture in a large cohort: a cross-sectional study (2021) (2)
Impaired renal function and colchicine toxicity. (1991) (2)
Diagnosis of early stage knee osteoarthritis based on early clinical course: data from the CHECK cohort (2021) (2)
"Spydergrams" to depict the results of the Short Form-36 questionnaire: a work in progress. (2013) (2)
[Prednisone for rheumatoid arthritis: the detriment of the doubt]. (2012) (2)
Comprar Rheumatoid Arthritis | Raashid Luqmani | 978-0-19-955675-5 | Oxford University Press (2010) (2)
Patient and rheumatologist perspectives on glucocorticoids an exercise to improve the implementation of the EULAR recommendations on the management of systemic glucocorticoid therapy in rheumatic diseases (2010) (2)
Response to secukinumab on synovitis using Power Doppler ultrasound in psoriatic arthritis: 12-week results from a phase III study, ULTIMATE (2021) (2)
AB1165 MEDICATION ADHERENCE DATA IN A RANDOMIZED TRIAL: LARGE CHALLENGES TO COME FROM RAW DATA TO A WORKABLE AND RELIABLE DATASET (2020) (2)
Diagnosis of early stage knee osteoarthritis based on early clinical course: data from the CHECK cohort (2021) (2)
Disease activity in women with ankylosing spondylitis remains higher under Tumour Necrosis Factor inhibitor treatment than in men: a five-year observational study (2021) (2)
OMERACT: An Ongoing Evidence‐Based Initiative to Improve the Quality of Outcome Measures in Rheumatology (2009) (2)
Patient perspective on remission in rheumatoid arthritis: Validation of patient reported outcome instruments to measure absence of disease activity. (2021) (2)
A Novel Method to Combine Assessment of Benefit and Harm: Outcome Measures in Rheumatology 3×3 Methodology Applied to Two Active Comparator Trials (2019) (2)
AB0230 STATINS TO PREVENT RHEUMATOID ARTHRITIS: INCONCLUSIVE RESULTS OF THE STAPRA TRIAL (2020) (2)
High Prevalence of Previously Undiagnosed Axial Spondyloarthritis in Patients Referred With Anterior Uveitis and Chronic Back Pain: The SpEYE Study (2022) (2)
Progress Towards Optimal Trial End-Points in Rheumatoid Arthritis (2012) (2)
OMERACT Conference on outcome measures in rheumatoid arthritis clinical trials : acknowledgements (1993) (2)
Bias in its coat of many colors. (2001) (2)
SP0057 Data Visualisation: Tables and Graphs for Publication and Presentation (2016) (2)
What is long-term control of atopic eczema? : International qualitative studies and results of the HOME V consensus meeting O27 (2018) (2)
Antirheumatic drugs for cardiovascular disease prevention: the case for colchicine (2021) (2)
A CORE OUTCOME MEASUREMENT SET FOR LOW BACK PAIN CLINICAL TRIALS (2018) (2)
The Added Value of Radiographs in Diagnosing Knee Osteoarthritis Is Similar for General Practitioners and Secondary Care Physicians; Data from the CHECK Early Osteoarthritis Cohort (2020) (2)
P187 Secukinumab significantly decreased joint synovitis measured by Power Doppler ultrasonography in biologic-naive patients with active psoriatic arthritis: primary (12week) results from a randomised, placebo-controlled Phase 3 study (2021) (2)
Interval prolongation of etanercept in rheumatoid arthritis, ankylosing spondylitis, and psoriatic arthritis: a randomized controlled trial (2022) (2)
The safety of glucocorticoids in the treatment of inflammatory rheumatic disease: new evidence (2022) (2)
Interactive conference voting. The OMERACT II Committee. Outcome Measures in Rheumatoid Arthritis Clinical Trial Conference. (1995) (2)
arthralgia: a randomised trial with levels and arthritis development in patients Effect of dexamethasone on autoantibody (2010) (2)
079. Do Ultrasound (Power Doppler Ultrasonography) and Disease Activity Score-28 Measure Different Aspects of Disease Activity? Analyses from an Open-Label Study of Power Doppler Ultrasonography Response Patients with Rheumatoid Arthritis Patients Starting Abatacept (2015) (2)
Glucocorticoid-trials in rheumatoid arthritis mostly study representative real-world patients: A systematic review and meta-analysis. (2020) (2)
Reply: Low-dose glucocorticoids in rheumatoid arthritis: blurring the line between therapeutic dose and substitution therapy? (2017) (1)
Towards developing diagnostic criteria for early knee osteoarthritis (2020) (1)
A multidisciplinary lifestyle program for rheumatoid arthritis: the "Plants for Joints" randomized controlled trial. (2023) (1)
OP0189 MACROPHAGE PET/CT IMAGING OF THE FEET CAN CONTRIBUTE TO EARLY PREDICTION OF THERAPY OUTCOME IN RHEUMATOID ARTHRITIS (2021) (1)
HOW OUTCOME MEASURES IN RHEUMATOID ARTHRITIS CLINICAL TRIALS WORKS TO DEVELOP OUTCOME MEASURES IN RHEUMATOLOGY CLINICAL TRIALSI116. CHOOSING AND DEVELOPING CORE OUTCOME MEASUREMENT SETS FOR CLINICAL TRIALS: OUTCOME MEASURES IN RHEUMATOID ARTHRITIS CLINICAL TRIALS FILTER 2.0 (2017) (1)
Multi-Systemic Auto-immune Diseases: An Integrated Approach. Dermatological and Internal Aspects, Kater L, Baart de la Faille H (Eds.). Elsevier, Amsterdam, New York (1995) (1995) (1)
AB0286 STATINS TO PREVENT RHEUMATOID ARTHRITIS (STAPRA TRIAL): CHALLENGES IN RECRUITMENT AND RETENTION (2019) (1)
Harms reported by patients in rheumatology drug trials: a systematic review of randomized trials in the cochrane library from an OMERACT working group. (2021) (1)
274 THE IMPACT OF DIFFERENT DESCRIPTIONS OF THE CLASSIFICATION CRITERIA OF KELLGREN AND LAWRENCE ON KNEE OSTEOARTHRITIS (2009) (1)
Discontinuation of Vioxx (2005) (1)
FRI0151 Incidence Rates of Skin Cancers During Exposure to Intravenous and Subcutaneous Abatacept in Patients with Rheumatoid Arthritis: Results from Pooled Clinical Trial Data (2015) (1)
Excessive Pricing Causes Poor Access to Biologics (2018) (1)
Long-term Glucocorticoid Use in Rheumatoid Arthritis (2020) (1)
THU0211 Six months after treatment discontinuation tnf is still in complex with adalimumab (2018) (1)
OP0006 Eular evidence-based recommendations on the management of medium to high dose systemic glucocorticoid therapy in rheumatic diseases (2013) (1)
FRI0317 Separate quantitative features of early radiographic knee osteoarthritis: Development over five years and relation with symptoms in the check cohort (2013) (1)
Three Months of Glucocorticoids in Rheumatoid Arthritis: A Bridge Too Short? (2022) (1)
[The predictive value of autoantibodies in disseminating lupus erythematosus and rheumatoid arthritis]. (2005) (1)
Effect of dosage on coxib- or nonsteroidal antiinflammatory drug-associated cardiovascular risk? Comment on the article by Solomon et al. (2007) (1)
Association Between Participant Retention and the Proportion of Included Elderly People in Rheumatology Trials: Results From a Series of Exploratory Meta‐Regression Analyses (2020) (1)
FRI0118 INFECTION OUTCOMES IN PATIENTS WITH RA TREATED WITH ABATACEPT AND OTHER DMARDS: RESULTS FROM A 10-YEAR INTERNATIONAL POST-APPROVAL STUDY (2019) (1)
Glucocorticoids in Rheumatic Diseases: Friend or Foe? (2007) (1)
Individual patient data meta-analysis on continued use of glucocorticoids after their initiation as bridging therapy in patients with rheumatoid arthritis (2022) (1)
Identifying barriers and solutions concerning the recruitment and retention of elderly people in clinical research: Protocol for a Systematic Review (2020) (1)
Combination treatment in autoimmune diseases. Methodology of combination trials. (2001) (1)
OP0209 INTERVAL PROLONGATION IN ETANERCEPT-TREATED PATIENTS WITH RHEUMATOID ARTHRITIS, ANKYLOSING SPONDYLITIS OR PSORIATIC ARTHRITIS: AN OPEN-LABEL, RANDOMISED CONTROLLED TRIAL (2020) (1)
Evidence for interaction between disease severity and comorbidity in rheumatoid arthritis? comment on the article by Navarro-Cano et al. (2004) (1)
Diagnosis for early stage knee osteoarthritis: probability stratification, internal and external validation; data from the CHECK and OAI cohorts. (2022) (1)
SAT0217 Long Term Effects of Glucocorticoid Therapy on Radiological Progression of Joint Damage in Rheumatoid Arthritis: An Individual Patient Meta-Analysis (2015) (1)
Chapter 1 Epidemiology, genetics and economic burden of rheumatoid arthritis (2010) (1)
COBRA combination therapy in daily practice--getting back to the future. (2008) (1)
SAT0114 Poor cardiovascular risk management in rheumatoid arthritis patients despite an explicit cardiovascular risk management program (2017) (1)
SAT0551 WHOLE BODY MACROPHAGE PET IMAGING THAT INCLUDES THE FEET CAN PROVIDE ADDITIONAL INFORMATION TO CLINICAL ASSESSMENT IN PATIENTS WITH EARLY RHEUMATOID ARTHRITIS (2020) (1)
SAT0125 Comparing the long-term clinical outcome of etanercept and adalimumab treatment with respect to immunogenicity (2013) (1)
Evaluating Positron Emission Tomography in Non-small cell Lung Cancer: Moving Beyond Accuracy to Outcome (2008) (1)
A CORE OUTCOME SET FOR CLINICAL TRIALS IN NON-SPECIFIC LOW BACK PAIN (2016) (1)
THU0635 Defining The Optimal Biological Monotherapy in Rheumatoid Arthritis: A Systematic Review and Network Meta-Analysis of Randomised Trials (2016) (1)
Use of composite outcomes facilitate core outcome set uptake in rheumatoid arthritis trials (2019) (1)
Cost-Effectiveness of Biologics in Early Rheumatoid Arthritis (2010) (1)
The GLORIA adherence subproject: problems and randomization mistakes (2021) (1)
OP0263 FAVORABLE BALANCE OF BENEFIT AND HARM OF LONG-TERM, LOW-DOSE PREDNISOLONE ADDED TO STANDARD TREATMENT IN RHEUMATOID ARTHRITIS PATIENTS AGED 65+: THE PRAGMATIC, MULTICENTER, PLACEBO- CONTROLLED GLORIA TRIAL (2022) (1)
Why publish a secondary analysis of only one treatment group in the Behandelstrategieën voor Reumatoide Artritis trial? Comment on the article by van der Bijl et al. (2007) (1)
Consensus on the need for a hierarchical list of patient-reported pain outcomes for meta-analyses of knee osteoarthritis trials (2015) (1)
Does the sex of rheumatoid arthritis patients matter (1998) (1)
FRI0229 Risk of Hospitalized Infections in Patients with Rheumatoid Arthritis Initiating Abatacept and Other Biologics: Analysis of A United States Claims Database (2016) (1)
Routine treatment of rheumatoid arthritis with biologics and targeted agents: changes in patients and their response over 15 years (2022) (1)
Improving benefit-harm assessment of glucocorticoid therapy incorporating the patient perspective: The OMERACT glucocorticoid core domain set. (2021) (1)
Risk of Serious Adverse Effects and Death Associated with Biological and Targeted Synthetic Disease-Modifying Anti-Rheumatic Drugs in Patients with Rheumatoid Arthritis : Protocol for a Systematic Review and Meta-analysis of Randomized Controlled Trials (2014) (1)
RECOMMENDATIONS FOR THE REGISTRATION OF DRUGS TO TREAT SARCOPENIA (2015) (1)
Cross-cultural validity of the Animated Activity Questionnaire (AAQ) for assessing activity limitations in patients with hip or knee osteoarthritis (2015) (1)
OP0314 Is Cardiovascular Risk Management in Patients with Rheumatoid Arthritis Effective? Two Year Follow Up Reveals Unexpected Rise in Cardiovascular Risk! (2015) (1)
Effects of Co-medication with Glucocorticoids in Biologics Trials (2018) (1)
Systematic review of rheumatoid arthritis clinical studies: Suboptimal statistical analysis of radiological data. (2019) (1)
Remarkable international variability in reasons for ineligibility and non-participation in the GLORIA trial (2019) (1)
Favorable effect of a 'second hit' after 13 weeks in early RA non-responders: The Amsterdam COBRA treat-to-target randomized trial. (2022) (0)
[Treatment of rheumatoid arthritis by inhibition of tumor necrosis factor with infliximab or etanercept]. (2001) (0)
A novel method to combine assessment of benefit and harm: OMERACT 3x3 methodology applied to two active comparator trials (2018) (0)
A breathtaking patient (2002) (0)
Evaluation of the wear-and-tear scale for therapeutic footwear, results of a generalizability study. (2018) (0)
Combining technical and organisational elements in layer of protection analysis (2005) (0)
AB0364 Remarkable international variability in reasons for non-participation in the gloria trial (2018) (0)
Early prediction of treatment response in rheumatoid arthritis by quantitative macrophage PET (2022) (0)
THU0677 Outcome measurement instruments for safety in rheumatology: a scoping review of available instruments to inform the omeract safety working group (2017) (0)
SARS-CoV-2 Delta Breakthrough Infections in Vaccinated Patients with Immune-Mediated Inflammatory Diseases Using Immunosuppressants – Data from Two Controlled Prospective Cohort Studies (2022) (0)
The Journal of Rheumatology Measurements to Enhance Detection of Patients with Rheumatoid Arthritis is a Novel Marker that Complements Current Serological η Serum 14-3-3 (2014) (0)
OP0226 TOWARDS DEVELOPMENT OF AN ULTRASOUND ENTHESITIS SCORE IN PSORIATIC ARTHRITIS: 24-WEEK RESULTS FROM THE PHASE III RANDOMISED ULTIMATE STUDY (2021) (0)
Comprar Evidence-Based Rheumatology | Michael J. Gibney | 9780727914460 | Wiley (2009) (0)
OP0202 Omeract Method of Combined Reporting of Benefit and Harm Applied to the TEAR Trial (2014) (0)
OP0106 Change in Bone Mineral Density with High-Dose Prednisone in Patients with Rheumatoid Arthritis (2016) (0)
Older Drugs With Limited Trial Evidence: Are They Worth the Expense? (2019) (0)
SAT0583 DEVELOPMENT AND TESTING OF A SMARTPHONE APPLICATION TO SELF-MONITOR DISEASE ACTIVITY IN RHEUMATOID ARTHRITIS (2019) (0)
Negligible Long-Term Effects on Bone Density after Four years of Treatment with Two Intensive Combination Strategies, including initially High dose Prednisolone, in Early Rheumatoid Arthritis patients: The COBRA-light Trial. (2017) (0)
THU0064 Short and Sustained Periods of ACR/EULAR Remission Predict Good Functional Outcome, but Not Stable Radiographic Outcome in Early Rheumatoid Arthritis (2016) (0)
Chronological or random reading of radiographs in long term follow-up studies of Rheumatoid Arthritis? (2009) (0)
Recurrent Laryngeal Carcinoma Pet Study (Relaps): Cost Analysis Of 18f-Fdg Pet In Patients With Suspected Recurrent Laryngeal Cancer Previously Treated With Radiotherapy. (2015) (0)
prospective trial data rheumatoid arthritis: published evidence and Safety of low dose glucocorticoid treatment in (2008) (0)
[Meta-analysis: the art of the systematic overview]. (1993) (0)
Development and Validation of a Long Term Gout Response Criterion Objective and Specific Aims (0)
SAT0037 14-3-3 ETA Sero-Positivity Marks More Severe Disease and Titres Inform Response to Therapy, also in Patients with Lower Crp (2013) (0)
SAT0050 Intensive Combination Treatment Regimens, Including Prednisolone, Are Effective in Treating Early Rheumatoid Arthritis Patients Regardless of Additional Etanercept: 1 Year Results of the Cobra-Light Trial (2014) (0)
OP0294 REDUCED JOINT SYNOVITIS ASSESSMENT VERSUS THE GLOBAL EULAR OMERACT SYNOVITIS SCORE (GLOESS) TO PREDICT THE RESPONSE TO SECUKINUMAB IN PATIENTS WITH ACTIVE PSORIATIC ARTHRITIS AND INADEQUATE RESPONSE TO CONVENTIONAL DISEASE-MODIFYING ANTI-RHEUMATIC DRUGS: EXPLORATORY RESULTS FROM THE ULTIMATE (2022) (0)
Shigellosis and AIDS. Report of a case and brief review of the literature. (1989) (0)
A review on safety : published evidence Low-dose glucocorticoid therapy in rheumatoid (2005) (0)
Clinical guidelines: Can wise choices solve the health-care crisis? (2013) (0)
The Journal of Rheumatology MethodologyInstrument Selection Using the OMERACT Filter 2.1: The OMERACT (2020) (0)
in rheumatic diseases management of systemic glucocorticoid therapy EULAR evidence-based recommendations on the (2008) (0)
Immunology of rheumatoid arthritis (1999) (0)
AB0396 EFFECT OF A MULTIDISCIPLINARY LIFESTYLE PROGRAM IN PATIENTS WITH RHEUMATOID ARTHRITIS: THE PLANTS FOR JOINTS RANDOMIZED CONTROLLED TRIAL (2022) (0)
MRI for the early detection of sacroiliitis. (2000) (0)
Whole-Body Macrophage Positron Emission Tomography Imaging for Disease Activity Assessment in Early Rheumatoid Arthritis (2022) (0)
Correspondence on "Testing different thresholds for patient global assessment in defining remission for rheumatoid arthritis: are the current ACR/EULAR Boolean criteria optimal?" by Studenic et al (2023) (0)
THU0121 The interferon type I signature towards prediction of non-response to rituximab in rheumatoid arthritis patients (2013) (0)
A machine learning approach reveals features related to clinicians' diagnosis of clinically relevant knee osteoarthritis. (2022) (0)
Comment on: Rheumatoid arthritis disease activity and hospitalized infection in a large U.S. registry: some additional suggestions for analyses by Yun et al. (2022) (0)
Erratum to “Updated Consolidated Standards of Reporting Trials (CONSORT): it just gets better” [J Clin Epidemiol 2010;63:813–814] (2011) (0)
POS0971 THE RELATIONSHIP OF AXIAL [18F]FLUORIDE UPTAKE ON PET-CT TO ANATOMICAL CHANGES ON MRI AND X-RAY IN CLINICALLY ACTIVE ANKYLOSING SPONDYLITIS PATIENTS (2022) (0)
SP0168 Theory of poster design and presentation (2017) (0)
SAT0470 Unblinding the sequence when reading radiographs in rheumatoid arthritis increases efficiency and does not lead to bias (2013) (0)
Comment on: Evidence for interaction between disease severity and comorbidity in rheumatoid arthritis? By Navarro-cano et al (2004) (0)
OP0015 Mortality of the cobra early rheumatoid arthritis trial cohort after 23 years follow up (2018) (0)
5th National Congress of the Italian Society of Physiotherapy (2016) (0)
SAT0464 Remission at 6 as well as at 9 months predicts good long-term outcome in early rheumatoid arthritis patients with non-biological treatment (2013) (0)
Development and testing of a computerized animated activity questionnaire (AAQ) for assessing activity limitations in patients with hip and knee osteoarthritis (2015) (0)
OP0260 RESPONSIVENESS OF A COMBINED POWER DOPPLER AND GREYSCALE ULTRASOUND SCORE FOR ASSESSING SYNOVITIS AT JOINT LEVEL IN PSORIATIC ARTHRITIS PATIENTS WITH INADEQUATE RESPONSE TO csDMARDs: DATA FROM THE ULTIMATE TRIAL (2022) (0)
AB0466 Glucocorticoid Effect on Radiographic Progression in Rheumatoid Arthritis BIOLOGICS Trials (2014) (0)
Uses of error. A breathtaking patient. (2002) (0)
Chapter 2 . 2 Pharmacogenomics in rituximab treated rheumatoid arthritis patients 2 . 2 B The interferon type I signature towards prediction of non-response to rituximab in rheumatoid arthritis patients (2013) (0)
Association between trial retention and the proportion of included elderly individuals: Protocol for a meta-research project v1 (2018) (0)
In RA patients without prevalent CVD, incident CVD is mainly associated with traditional risk factors: A 20-year follow-up in the CARRÉ cohort study. (2022) (0)
SAT0241 Patients’ perspective on the efficacy and risks of glucocorticoids in ra – an initiative under the gloria project (2018) (0)
SP0156 Theory of poster design and presentation (2018) (0)
AB0779 7 Years of Follow-Up of Early Symptomatic Oa: Characteristics of CHECK (Cohort HIP & Cohort Knee) (2014) (0)
SP0146 Improving Your Graphs and Tables for Publication and Presentation (2014) (0)
Reply (2019) (0)
[Roaming through methodology. XXV. Outcome measures, surrogate outcomes, and intermediate measures]. (2000) (0)
SP0187 How do we combine modern imaging in the RA remission criteria? (2013) (0)
Boers, A. M.M. et al. (2018) Association of follow-up infarct volume with functional outcome in acute ischemic stroke: a pooled analysis of seven (2018) (0)
PAM20: COST-EFFECTIVENESS OF ACETYLCISTEINE AND DIMETHYLSULPHOXIDE (DMSO) 50% FOR THE TREATMENT OF PATIENTS WITH REFLEX SYMPATHIC DYSTROPHY (2001) (0)
THU0145 Novel Peptide Biomarkers Detected by Mass Spectrometry Predict Arthritis in Seropositive Arthralgia Patients (2013) (0)
SAT0152 High Cardiovascular Risk in Patients with Rheumatoid Arthritis: is Screening Effective? (2014) (0)
where necessary, can lead to new levels of disease control in early RA. (2011) (0)
Patient-Reported Outcomes Measurement Information System® Adult V1.0 Item Banks--Dutch-Flemish Version (2018) (0)
SAT0130 Defining the Optimal Biological Monotherapy in Rheumatoid Arthritis (RA): Network Meta-Analysis of Randomized Trials (2013) (0)
SP0059 Remission: more than clinical ...? (2017) (0)
OP0013 Effective Treatment Rapidly Improves both Disease Activity and Physical Activity in Early Rheumatoid Arthritis (2015) (0)
Change in bone mineral density with high-dose prednisone in patients with rheumatoid arthritis (2016) (0)
Dutch-Flemish translation of the PROMIS item banks (2012) (0)
Methodological Quality Assessment of Randomised Clinical Trials (1996) (0)
Characteristics of check (cohort hip & cohort knee): after 7 years of follow-up (2014) (0)
Mortality has improved in RA, but we must remain vigilant. Response to: ‘Early intensive treatment normalises excess mortality in ACPA-negative RA but not in ACPA-positive RA’ by Matthijssen et al (2019) (0)
CHAPTER 11A – Design of Trials for New Therapies in Patients with Rheumatoid Arthritis (2009) (0)
Generic measures to compare burden of disease. (1999) (0)
[18F]Fluoride PET provides distinct information on disease activity in ankylosing spondylitis as compared to MRI and conventional radiography (2022) (0)
E087 Reduced joint synovitis assessment versus the global EULAR OMERACT synovitis score (GLOESS) to predict the response to secukinumab in patients with active psoriatic arthritis and inadequate response to conventional disease-modifying anti-rheumatic drugs: exploratory results from the ULTIMATE tr (2023) (0)
FRI0285 The Effect of Steroids on Fracture, Adjusting for Bone Mineral Density (2015) (0)
THU0045 Score and framingham predict cv disease incidence in RA patients better than intima-media thickness (2013) (0)
[To do a post-mortem is to look ahead; the future of autopsies]. (1990) (0)
Glucocorticoids for rheumatoid arthritis in the era of targeted therapies. (2019) (0)
OP0262 Similar Clinical and Radiological Outcome in The Cobra and Cobra-Light Treatment Group 4 Years after Initiation of The Cobra-Light Trial (2016) (0)
THU0599 Validation of the Dutch-Flemish Promis Pain Behavior and Pain Interference Item Banks in Patients with Rheumatoid Arthritis (2015) (0)
THU0703 Systematic review of rheumatoid arthritis clinical studies: suboptimal statistical analysis of radiological data (2017) (0)
THU0563 Validation of the Dutch-Flemish PROMIS Pain Behavior and Pain Interference Item Banks in Patients with Chronic Pain (2014) (0)
A New Concept of Health Can Improve the Definition of Frailty (2015) (0)
FRI0521 A framework and process to develop core outcome measurement sets for clinical trials in rheumatology: omeract filter 2.0 (2013) (0)
THU0141 Long-term effects on bone mineral density after four years of treatment with two intensive combination strategies, including initially high dose prednisolone, in early rheumatoid arthritispatients: the cobra-light trial (2018) (0)
OP0261 One-Year Effects of Glucocorticoids on Bone Density. A Meta-Analysis in Cohorts of Patients on High and Low Dose Therapy (2014) (0)
Bone loss in early, active rheumatoid arthritis: Effects of corticosteroids, gender and menopausal status in the Cobra trial (2000) (0)
Glucocorticoids for rheumatoid arthritis in the era of targeted therapies (2019) (0)
FRI0309 Cardiovascular events in anca-associated vasculitis: a meta-analysis of observational studies (2017) (0)
Changes to the AHVLA services (2011) (0)
Antibody Development after SARS-CoV-2 Vaccinations in Elderly Patients with Autoimmune Diseases: Data From a Prospective Controlled Cohort Study (2021) (0)
Treatment Intensification Based on Disease Activity (2004) (0)
Chapter 3 Diagnosis and clinical features of rheumatoid arthritis (2010) (0)
POS0379 SMARTPHONE-ASSISTED PATIENT-INITIATED CARE VERSUS USUAL CARE IN PATIENTS WITH RHEUMATOID ARTHRITIS AND LOW DISEASE ACTIVITY: A RANDOMIZED CONTROLLED TRIAL (2022) (0)
Pyridinoline excretion is related to bone loss abd cartilage damage in early active rheumatoid arthritis (2000) (0)
217 Results of a patient survey on feasibility and face validity of outcome measures for intended use in future studies enrolling participants with polymyalgia rheumatica (2019) (0)
AB0306 The influence of the definition of patient global assessment in assessment of ACR/eular remission and minimal disease activity in rheumatoid arthritis: A 3-month cohort study in patients starting etanercept (2013) (0)
SP0092 ‘SCIENTIFIC DATA VISUALIZATION: FOCUS ON (POSTER) PRESENTATION (2019) (0)
POS0213 20 Year Follow-Up Of Cardiovascular Event Risk In Rheumatoid Arthritis Compared To Diabetes (2021) (0)
SP0093 Using Literature to Solve Clinical Problems (2013) (0)
AB0166 PROTOCOL VIOLATIONS IN AN OPEN, RANDOMIZED, TRIAL IN EARLY RA PATIENTS: POTENTIAL IMPACT OF SHARED DECISION MAKING (2022) (0)
Dexamethasone in the primary prevention of rheumatoid arthritis: a randomized trial (2011) (0)
COBRA treatment strategy in early rheumatoid Why are Dutch rheumatologists reluctant to use the (2007) (0)
POS0197 RESPONSIVENESS OF ULTRASOUND SYNOVITIS AND CLINICAL OUTCOMES IN PSORIATIC ARTHRITIS TREATED WITH SECUKINUMAB: DATA FROM THE ULTIMATE TRIAL (2021) (0)
FRI0552 Systematic review of patient reported outcome measures used to measure stiffness in patients with rheumatoid arthritis (2013) (0)
SAT0334 Three Trajectories of Activity Limitations in Early Symptomatic Knee Osteoarthritis: a 5-Year Follow-Up Study (2013) (0)
Cardiovascular disease and Rheumatoid Arthritis (2011) (0)
SAT0177 Safety events are similar with abatacept vs placebo treatment in ra: results from integrated data analysis from nine clinical trials (2017) (0)
SAT0051 Alternative Ways to Analyze Remission: Applying the Conrew Score and Patient Vector Graph to Camera –Trial II Data (2014) (0)
Feasibility of Self-Monitoring Rheumatoid Arthritis With a Smartphone App: Results of Two Mixed-Methods Pilot Studies (Preprint) (2020) (0)
Two-year clinical follow-up from the onset of complaints is predictive for the early diagnosis of hip osteoarthritis (2020) (0)
OP0014 NO ASSOCIATION BETWEEN THE PROPORTION OF ELDERLY PEOPLE AND TRIAL RETENTION IN RHEUMATOID ARTHRITIS AND OSTEOARTHRITIS TRIALS: A SYSTEMATIC REVIEW WITH META-REGRESSION ANALYSES (2019) (0)
OP0270 TAPERING OF LONG-TERM, LOW-DOSE GLUCOCORTICOIDS IN SENIOR RHEUMATOID ARTHRITIS PATIENTS: FOLLOW-UP OF THE PRAGMATIC, MULTICENTRE, PLACEBO-CONTROLLED GLORIA TRIAL (2022) (0)
Using adalimumab serum concentration to choose a subsequent biological DMARD in rheumatoid arthritis patients failing adalimumab treatment (ADDORA-switch): study protocol for a fully blinded randomised superiority test-treatment trial (2021) (0)
Layer of protection analysis: Selecting cost effective safety measures (2006) (0)
AB0226 Decline in anti-ccp and rheumatoid factor levels in patients with early rheumatoid arthritis after 2 years of treatment with intensive combination strategies, including prednisolone: the cobra-light trial (2018) (0)
Development and Evaluation of a Smartphone Application for Self-Monitoring of Rheumatoid Arthritis Disease Activity: Results of Two Pilot Studies and Design of a Randomized Controlled Trial (Preprint) (2019) (0)
FRI0224 A New Method to Assess Activity Limitations in Patients with Hip and Knee Osteoarthritis: the Animated Activity Questionnaire (AAQ): Part 1. Development, Validity and Reliability (2014) (0)
Osteoarthritis and Cartilage Vol . 17 , Supplement 1 S 149 Clinical Aspects / Outcomes (2009) (0)
PARE0004 PATIENT PERSPECTIVE ON THE EFFICACY AND RISKS OF GLUCOCORTICOIDS IN RHEUMATOID ARTHRITIS – AN INTERNATIONAL SURVEY OF 1344 PATIENTS (2020) (0)
More erronous statements about the use of frequentist statistical methods in medical research. (2019) (0)
AB1335-HPR HEALTH PROFESSIONALS’ PERSPECTIVE ON THE BENEFITS AND RISKS OF LOW-DOSE GLUCOCORTICOIDS IN RHEUMATOID ARTHRITIS – AN INTERNATIONAL SURVEY OF 444 HEALTH PROFESSIONALS (2020) (0)
Separate quantitative features of early radiographic knee osteoarthritis: development over five years and relation with symptoms in the check cohort (2012) (0)
A MACHINE LEARNING APPROACH REVEALS FEATURES RELATED TO CLINICALLY RELEVANT KNEE OSTEOARTHRITIS; DATA FROM THE CHECK COHORT (2022) (0)
Thanks to Reviewers2015 (2015) (0)
Receptor activator of the nuclear factor kappa-b ligand (RANKL) in the serum of patients with RA is strongly coupled to rheumatoid-factor presence, and predicts long-term radiologic progression. (2002) (0)
FRI0047 The Patient Perspective on Absence of Disease Activity in Rheumatoid Arthritis: A Survey to Identify Key Domains of Patient Perceived Remission (2015) (0)
Zoledronate in the prevention of Paget(cid:146)s (ZiPP): protocol for a randomised trial of genetic testing and targeted zoledronic acid therapy to prevent SQSTM1 mediated Paget(cid:146)s disease of bone (2019) (0)
AB1360 Gastrointestinal events in patients receiving NSAIDs for rheumatic diseases in routine practice: The pan-european evidence study (2013) (0)
THU0712 Dutch norm scores for four dutch-flemish promis item banks important for patients with rheumatoid arthritis (2017) (0)
SP0091 Data visualisation: tables and graphs for publication and presentation (2017) (0)
SP0046 Improving your Graphs for Publications (2013) (0)
Communicating with the APHA (2018) (0)
Intensive combination therapy in early rheumatoid arthritis (1998) (0)
SP0163 Improving Your Graphs and Tables for Publication and Presentation (2015) (0)
Instruments Through Assessment of ''Truth'': Content, Face, and Construct Updating the OMERACT Filter: Implications of Filter 2.0 to Select Outcome (2014) (0)
SAT0531 Association between Presence of Subclinical Synovitis on (R)-11C-PK11195 Positron Emission Tomography and Clinical Outcome in Rheumatoid Arthritis Patients without Clinical Synovitis (2013) (0)
Comment on: Paradoxically protective effect of glucocorticoids on bone mass and fragility fracture in a large cohort: a cross-sectional study. Reply (2022) (0)
Proceedings of the Second Update on Psoriatic Disease, University Federico II Congress Center, July 6–7, 2011, Naples, Italy. (2012) (0)
Meta-Analysis Suggests Intensive Non-Biologic Combination Therapy with Step-Down Prednisolone May Also 'Disconnect' Disease Activity and Damage in Rheumatoid Arthritis. (2011) (0)
SAT0127 Unfavorable body composition already at the onset of clinical arthritis (2017) (0)
Trilateral retinoblastoma (0)
A suggestion and the larger perspective on the American College of Rheumatology/European League Against Rheumatism remission definitions: comment on the article by Felson et al Reply (2011) (0)
Self-monitoring combined with patient-initiated care in RA patients with low disease activity: cost-effectiveness analysis of an RCT. (2023) (0)
HEALTH ECONOMICS IN OSTEOARTHRITIS (2013) (0)
Established rheumatoid arthritis: Preface (2003) (0)
Development of a provisional core domain set for polymyalgia rheumatica: Report from the Outcome Measures in Rheumatology (OMERACT) 12 polymyalgia rheumatica working group (2016) (0)
OP0141-HPR An innovate measurement instrument to assess activity limitations in hip and knee osteoarthritis: the computerized animated activity questionnaire (AAQ) and its psychometric properties (2017) (0)
FRI0600 Methods for the analysis of adherence data from a medication event monitoring system (MEMS): a systematic review (2018) (0)
Measurements to Enhance Detection of Patients with Rheumatoid Arthritis is a Novel Marker that Complements Current Serological η Serum 14-3-3 (2014) (0)
POS1410 DEVELOPMENT OF PREDICTION MODELS FOR SENIOR PATIENTS WITH RHEUMATOID ARTHRITIS AND COMORBIDITIES TREATED WITH CHRONIC LOW-DOSE GLUCOCORTICOIDS IN THE GLORIA TRIAL (2022) (0)
Cost-effectiveness and cost-utility of add-on, low-dose prednisolone in patients with rheumatoid arthritis aged 65+: the pragmatic, multicenter, placebo-controlled GLORIA trial (2022) (0)
Reporting Ultrasound Studies in RMDs 2 (2021) (0)
SP0069 How to Get Validated Indices Accepted as Outcome Measures in Clinical Trials (2014) (0)
Metacarpophalangeal implant surgery: time for a randomized clinical trial? Comment on the article by Chung et al (2013) (0)
of an Item Pool to Measure Functioning and Health ICF : First Step Towards an Improved Domain Specification and Development Examining the Similarities and Differences of OMERACT Core Sets Using the BOONEN (2011) (0)
Response to: Comment on l’Ami et al titled ‘Successful reduction of overexposure in patients with rheumatoid arthritis with high serum adalimumab concentrations: an open-label, non-inferiority, randomised clinical trial’ by den Broeder et al (2017) (0)
AB0384 THE EFFECT OF A LIFESTYLE PROGRAM ON PATIENTS AT RISK FOR RHEUMATOID ARTHRITIS:THE “PLANTS FOR JOINTS” PILOT RANDOMIZED CLINICAL TRIAL (2022) (0)
Evaluation Of The Diagnostic Abilities Of Acr, Eular And Nice Criteria Against Clinically Relevant Knee Osteoarthritis; Data From The Check Cohort (2023) (0)
Cross-cultural validation of the computerized animated activity questionnaire to assess activity limitations in patients with hip and knee osteoarthritis (2016) (0)
Clinical measures in rheumatoid arthritis: which are most useful in assessing patients? (1994) (0)
Diagnosis of early stage knee osteoarthritis: probability stratification, internal and external validation; data from the check and oai cohorts (2021) (0)
Validation of the Dutch-Flemish PROMIS Pain Behavior and Pain Interference Item Banks in Patients with Rheumatoid Arthritis (2015) (0)
Development of prediction models to select older RA patients with comorbidities for treatment with chronic low-dose glucocorticoids (2022) (0)
AB1223 RHEUMATOID ARTHRITIS PATIENTS INCLUDED IN GLUCOCORTICOID TRIALS MOSTLY RESEMBLE THOSE SEEN IN OBSERVATIONAL COHORTS: A SYSTEMATIC REVIEW AND META-ANALYSIS (2020) (0)
AB0184 Applying the conrew score to camera -trial ii data (2013) (0)
THU0104 Limited Safety Signals, but No Advantage of Cobra-Light over Cobra Combination Therapy 4 Years after Initiation of The Cobra-Light Trial in Early Rheumatoid Arthritis (2016) (0)
AB0160 HIGH NUMBER OF CONCOMITANT MEDICATIONS AND COMORBIDITIES AT BASELINE IN THE GLUCOCORTICOID LOW-DOSE OUTCOME IN RHEUMATOID ARTHRITIS (GLORIA) STUDY: AN OLDER POPULATION WITH RHEUMATOID ARTHRITIS (2021) (0)
SP0174 Eular points to consider when conducting long term extension studies of trials? (2013) (0)
Thanks to Reviewers—2020 (2020) (0)
arthritis?treatment strategy in early rheumatoid Why are Dutch rheumatologists reluctant to use the (2007) (0)
AB1410-HPR Health professionals’ perspective on benefits and risks of low dose glucocorticoids in ra – an initiative under the gloria project (2018) (0)
Public/private partnerships, at what price? (2020) (0)
Alternative Ways to Quantify Sustained Remission: Applying the Continuity Rewarded Score and Patient Vector Graph (2015) (0)
91% Of Early RA Patients Are Positive For Serum 14-3-3 eta Or Its Auto-Antibodies (2013) (0)
Seminars in clinical epidemiology and decision analysis: a new series in the journal (1995) (0)
and differences with the Osteoarthritis Initiative CHECK (Cohort Hip and Cohort Knee): similarities (2009) (0)
THU0564 Validation of the Dutch-Flemish PROMIS Physical Functioning Item Bank in Patients with Chronic Pain (2014) (0)
OP0102-HPR Cross-Cultural Validity of the Animated Activity Questionnaire (AAQ) that Assesses Activity Limitations in Patients with HIP or Knee Osteoarthritis (2015) (0)
Managing the selection of placebo group switched to experimental treatment group in post-randomised controlled trial extension studies (2022) (0)
Systematic review of the cost e V ectiveness of prophylactic treatments in the prevention of gastropathy in patients with rheumatoid arthritis or osteoarthritis taking non-steroidal anti-inﬂammatory drugs (2000) (0)
Efficacy of Tocilizumab Relative to Other Biologic Agents in Patients with Rheumatoid Arthritis and An Inadequate Response to Traditional Dmards: A Meta-Analysis with Mixed-Treatment Comparisons (2009) (0)
POS1480-HPR SCREENING WITH THE ROUTINE ASSESSMENT OF PATIENT INDEX DATA 3 QUESTIONNAIRE CAN REDUCE THE NUMBER OF CLINIC VISITS (2022) (0)
COMBINATION THERAPY IN RHEUMATOID ARTHRITIS. AUTHORS' REPLY (1999) (0)
FRI0581 IN ELDERLY PATIENTS, CAPS THAT RECORD MEDICATION BOTTLE OPENINGS ARE UNRELIABLE AND THUS NOT THE GOLD STANDARD FOR ADHERENCE (2020) (0)
Does updating improve the quality of reporting of systematic reviews ? (2005) (0)
Towards developing diagnostic criteria for early hip osteoarthritis (2020) (0)
SAT0620 Validation of The Dutch-Flemish Promis Fatigue Item Bank in Patients with Rheumatoid Arthritis (2016) (0)
THU0614-HPR ASSESSING THE EFFECT OF INTERVENTIONS FOR AXIAL SPONDYLOARTHRITIS ACCORDING TO THE ENDORSED ASAS/OMERACT CORE OUTCOME SET: A META-RESEARCH STUDY OF TRIALS INCLUDED IN COCHRANE REVIEWS (2020) (0)
WORKSHOP REPORT - HEALTH-STATUS INSTRUMENTS UTILITIES (1995) (0)
Calibration and validation of the Dutch-Flemish PROMIS fatigue item bank in patients with rheumatoid arthritis (2016) (0)
THU0062 Prognosis of Early Rheumatoid Arthritis Patients with Erosive Disease at Baseline (2016) (0)
SP0029 Improving Your Graphs and Tables for Publication and Presentation (2015) (0)
SP0080 Data visualisation: tables and graphs for publication and presentation (2018) (0)
Response to: ‘Tapering without relapse in rheumatoid arthritis patients with high TNF blocker concentrations: data from the STRASS study’ by Marotte et al (2019) (0)
AB0794 Development of a computerized animated activity questionnaire (aaq) to measure activity limitations in patients with hip and knee osteoarthritis. (2013) (0)
OMERACT: an international initiative to improve outcome measurement in rheumatology. (2005) (0)
Safety and efficacy associated with long-term low dose glucocorticoids in rheumatoid arthritis: a systematic review and meta-analysis. (2023) (0)
SP0197 Improving Your Graphs and Tables for Publication and Presentation (2014) (0)
Boers AMM, Jansen IGH, Beenen LF, et al. Association of follow-up infarct volume with functional outcome in acute ischemic stroke: a pooled analysis of seven randomized trials. Journal of Neurointerventional Surgery (2018) (2018) (0)
Prospective Validation of Soluble Biomarkers as Predictors of Structural Damage in Rheumatoid Arthritis (BIODAM) (2013) (0)
OP0007 Development of eular recommendations for the reporting of clinical trial extension studies (2013) (0)
Renalfindings inrheumatoid arthritis: clinical aspects of132necropsies (1987) (0)
244 AN UNIQUE EARLY OSTEOARTHRITIS COHORT OF HIP AND KNEE: THE CHECK STUDY (2007) (0)
Patient-Reported Outcomes Measurement Information System Physical Function Item Bank--Rheumatoid Arthritis (2021) (0)

This paper list is powered by the following services:

What Schools Are Affiliated With Maarten Boers?

Maarten Boers is affiliated with the following schools:

Maarten Boers's Academic­Influence.com Rankings

Maarten Boers's Degrees

Similar Degrees You Can Earn

Why Is Maarten Boers Influential?

Maarten Boers's Published Works

Published Works

What Schools Are Affiliated With Maarten Boers?

Maarten Boers's AcademicInfluence.com Rankings